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Excessive, non-traumatic bleeding and intravascular coagulation is prevented by a 
constant equilibrium of Virchow’s triad which comprises changes in blood composi-
tion, vessel wall properties and blood flow (1). An imbalance in Virchow’s triad towards 
coagulation may result in thrombotic events in venous or arterial systems. The most 
recognized entities of venous thromboembolic events (VTE) are deep vein thrombosis 
(DVT) of the leg and acute pulmonary embolism (PE) (2). Deep vein thrombosis is defined 
as the presence of thrombus in the deep vein system (3). It affects pre-dominantly the 
deep veins of the lower limbs. It must be distinguished from superficial thrombophlebi-
tis which has a more benign prognosis (4). Acute pulmonary embolism is defined as an 
acute thrombus in the pulmonary artery (3). VTE can be provoked or unprovoked based 
on the presence of contributing risk factors effecting Virchow’s triad. The most relevant 
risk factors for VTE include recent surgery or fracture of the lower extremity (odds ratio 
> 10), active malignancy (odds ratio 2-9), pregnancy or peri-partum period (odds ratio 
2-9), hormone replacement therapy and/or use of oral contraception (odds ratio 2-9), 
immobility for more than three days or a recent long flight (at least 4 hours) (odds ratio 
< 2) (5). Unprovoked VTE is defined as VTE occurring in the absence of known risk factors. 
Patients with DVT typically present with a painful, swollen leg, although non-specific 
symptoms of the calf muscle and lower extremities are common (6;7). The diagnosis has 
to be confirmed by compression ultrasonography, which is a highly accurate diagnostic 
test for detecting DVT (8). The classic presentation of pulmonary embolism is the sud-
den onset of pleuritic chest pain, shortness of breath, and hypoxia, although PE patients 
may present with a wide variety of symptoms ranging from non-specific thoracic pain, 
usually due to irritation of the visceral pleura, or gradually progressive dyspnea to sud-
den hemodynamic collapse (9;10). Because the signs and symptoms are non-specific, 
the diagnosis of pulmonary embolism should also be considered in patients with respi-
ratory symptoms unexplained by an alternative diagnosis. The preferred imaging test 
for patients suspected of having PE is computed tomography pulmonary angiography 
(CTPA) (3;11). CTPA is readily available in most hospitals and has been shown to have high 
sensitivity and specificity for PE, which is fully comparable with the traditionally golden 
standard invasive pulmonary angiography (12;13). Sensitivity is especially high in central 
PE compared to segmental and especially sub-segmental levels. However, the clinical 
significance of sub-segmental PE is highly debated and a lower sensitivity for these 
smaller emboli is therefore accepted (14;15). Notably, important concerns regarding the 
increased frequency of CTPA use are long-term radiation complications, allergic reac-
tions to iodinated contrast material and contrast-induced nephropathy (15-17). The latter 
complication is mainly present in patients with chronic kidney disease. The likelihood of 
this complication could be minimized by prophylactic protocols requiring intravenous 
fluid infusions like saline or sodium bicarbonate (18). Of note, the clinical risk for lifetime 
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need of renal replacement therapy due to contrast-induced nephropathy is very low 
(19). 
To reduce the number of required imaging tests, an algorithm has been introduced to 
enable ruling out suspected PE based on a clinical scoring system and a D-dimer blood 
test (3;20-22). Examples of such clinical scoring systems are the Wells rules for DVT and PE 
and the (revised) Geneva scores in PE patients (20;23;24). The Wells’ clinical decision rule 
for suspect PE is a scoring system based on objective signs, symptoms and risk factors 
of PE, which are assigned 1 till 3 points each, and a final subjective judgment, of treating 
clinicians regarding the likelihood of PE (3 points) (20). Using the Wells decision rule 
patients can be categorized in PE ‘unlikely’ (Wells score ≤ 4) or PE ‘likely’ (Wells score 
> 4) groups. In chapter 2 we systemically review and quantify whether anticoagulant 
therapy can safely be withheld without the need for any further radiological testing 
in patients with an “unlikely” Wells’ clinical decision rule in combination with a normal 
D-dimer test (<500 ng/ml). In chapter 3 we focus on the potential adverse events of 
iodized contrast media by conducting a meta-analysis to assess the risk of contrast 
induced nephropathy and the risk of renal replacement therapy after contrast enhanced 
computed tomography in patients with chronic kidney injury. We also evaluated specific 
patient subgroups for their risk of developing contrast induced nephropathy.
Pulmonary embolism is a potentially lethal condition (10;25). Mortality is thought to be 
caused by right ventricular pressure overload secondary to acute pulmonary hyperten-
sion caused by PE (26). Radiological findings and cardiac biomarkers can be applied to 
identify patients with PE at higher risk of adverse clinical outcome, i.e. hemodynamic 
collapse or death. This is clinically relevant since these patients might benefit from re-
perfusion therapy on top of standard anticoagulation (3). Radiological signs predicting 
worse outcome include thrombotic burden and right ventricular function (27). Recent 
studies have evaluated whether RV dysfunction can be assessed using CTPA. For ex-
ample, the ratio of RV to LV short-axis diameters was identified to be an accurate sign 
of RV dysfunction (27). Absence of RV dysfunction, described as a RV/LV ratio of 1.0 or 
less and a pulmonary artery obstruction index of 40%  or less, is predictive for an event 
free outcome (28). It can be plausibly assumed that a delay in diagnosis and treatment 
initiation may be a strong predictor of adverse outcome as well. Notably, recent studies 
have not been able to confirm this association and reported that a patients’ delay, i.e. 
time between symptom onset and presentation at the hospital, did not result in worse 
clinical outcome (29-32). chapter 4 reports on a study in patients with CTPA-proven PE 
in which we aimed to further investigate the impact of patient delay on PE prognosis 
by analyzing whether delay between symptom onset and presentation at the hospital 
influenced thrombotic burden and/or aggravated right ventricular function.
In addition to radiological signs of poor cardiac function, several biomarkers may 
predict adverse outcome after PE (33-35). A well-known cardiac biomarker that predicts 
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clinical outcome in PE is Brain-type Natriuretic Peptide (BNP). BNP is an amino-peptide 
predominantly excreted on hemodynamic changes by the myocytes in the left ventricle 
as pro-BNP (36). Pro-BNP is subsequently cleaved in the circulation into BNP and the 
inactive N-terminal-pro-BNP. The BNP release is directly proportional to the ventricular 
expansion and volume overload (37). The effects of BNP are vasodilatation, natriuresis 
and diuresis. These actions are thought to be primarily beneficial in pathological states 
of the left ventricle such as hypertension and compensated heart failure (38). Nonethe-
less, BNP levels are also raised in patients with acute PE, which predominantly affects the 
right ventricle and not the muscular left ventricle (39). To further understand the source 
of BNP release in acute PE, we analyzed associations between NT-pro-BNP levels and CT 
assessed right and left ventricular volumes and function in patients with and without PE 
(chapter 5).
The major pathophysiological mechanism of arterial thromboembolic events (ATE) is 
atherosclerosis. In short, atherosclerosis starts as fatty streaks caused by influx of lipids 
into the tunica intima, the innermost layer of artery walls (40). This initiates an inflam-
matory response with influx of monocytes, macrophages, T-cells and also platelets. 
Eventually, a protective fibrous cap is generated over fatty deposits (41). These lesions 
may fill the vascular lumen, lowering the post-lesion blood flow which ultimately results 
in transient ischemic disease such as angina pectoris in the coronary arteries, transient 
ischemic attack in the cerebral arteries or intermittent claudication in peripheral arteries 
(42). When this atherosclerotic plaque ruptures, a local thrombus is immediately formed 
that may cause a total obstruction of the arterial lumen causing acute ischemic disease 
as myocardial infarction and stroke (42). Most relevant non-genetic risk factors for ATE 
are smoking, hypertension, diabetes and hypercholesterolemia which are predomi-
nately diseases of the developed world but become also more and more prevalent in 
third world countries (43;44). Nonetheless, 80% of the worlds’ cardiovascular burden 
occurs in low-income and middle-income countries (44). The individual contribution of 
these risk factors for cardiovascular disease is not easy to assess, since patients often 
have combination of multiple risk factors. For instance, only a small fraction of the 
hypertensive population has an elevation of blood pressure alone, with the majority ex-
hibiting additional cardiovascular risk factors such as obesity or smoking (45). Notably, 
when concomitantly present, different risk factors may potentiate each other, leading 
to a total cardiovascular risk that is greater than the sum of its individual components 
(45). In chapter 6 we focus on the effect of blood pressure in the occurrence of athero-
sclerosis in a unique study population living on the island of Flores, Indonesia. This is a 
treatment naïve population with a traditional “non-western” life style at the secondary 
epidemiological transition, which means a high burden of infectious disease and low 
amount of cardiovascular diseases. In this population we studied carotid intima media 
thickness — as a marker of atherosclerosis — in relation to blood pressure class.
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Untill the beginning of the 21st century VTE and ATE were considered vascular diseases 
with different entities. However in 2003 a strong correlation between VTE and athero-
sclerosis was reported (48). In the latter study, ultrasonography of the carotid arteries 
was performed as a surrogate measurement of atherosclerosis in patients with DVT and 
healthy control patients. Carotid plaque was detected in 47.1% of the patients with un-
provoked DVT compared to 27.4% (odds ratio 2.3; 1.4-3.7) of the patients with provoked 
DVT, and 32.0% (odds ratio 1.8; 1.1-2.9) in healthy control patients. These results indicated 
an association between ATE and VTE. In the years following his publication, several dif-
ferent studies have reported a higher incidence of ATE in patients with unprovoked VTE 
when compared to patients with provoked VTE or in whom VTE was suspected but ruled 
out by radiological examination (49-52). A meta-analysis showed that these findings 
could partly be explained by individual cardiovascular risk factors including obesity and 
hypertension, although the exact mechanisms remains unknown (53). Most of the stud-
ies on this subject included patients with VTE in general or with acute PE only, and did 
not focus solely on DVT patients. We assessed the incidence of ATE in patients with a first 
episode of compression ultrasonography proven provoked and unprovoked proximal 
DVT and compared them with the incidence of ATE in patients in whom DVT was clini-
cally suspected but ruled out (chapter 7). In chapter 8 we summarize and discuss the 
results of the studies presented in this thesis.
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Chapter 2 
Safety of excluding acute 
pulmonary embolism based on an 
unlikely clinical probability by the 
wells rule and normal D-dimer 
concentration: a meta-analysis
S.M. Pasha, F.A. Klok, J.D. Snoep, I.C.M. Mos, R.J. Goekoop,
M.A. Rodger, M.V. Huisman




The Wells clinical decision rule (CDR) and D-dimer tests can be used to exclude pulmo-
nary embolism (PE). We performed a meta-analysis to determine the negative predictive 
value (NPV) of an “unlikely” CDR (≤ 4 points) combined with a normal D-dimer test and 
the safety of withholding anti-coagulants based on these criteria.
Methods
Prospective studies that withheld anti-coagulant treatment from patients with clinically 
suspected PE and an “unlikely” CDR in combination with a normal D-dimer concentration 
without performing further tests were searched for in Medline, Cochrane and Embase. 
Primary endpoints were the recurrence rate of venous thromboembolism (VTE) and PE-
related mortality during 3-months follow-up.
Results
Four studies including 1660 consecutive patients were identified. The pooled incidence 
of VTE after initial exclusion of acute PE based on an “unlikely” CDR and normal D-dimer 
was 0.34% (95%CI 0.036-0.96%), resulting in a NPV of 99.7% (95%CI: 99.0-99.9%, random 
effects-model). The risk for PE related mortality was very low: 1/1660 patients had fatal 
PE (0.06%, 95%CI 0.0017-0.46%). 
conclusion
Acute PE can be safely excluded in patients with clinically suspected acute PE who have 
an “unlikely” probability and a negative D-dimer test and anticoagulant treatment can 
be withheld. There is no need for additional radiological tests in these patients to rule 
out PE. 
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INTRODUcTION
The possibility of excluding the diagnosis of acute pulmonary embolism (PE) without 
the need for radiological imaging is a great step forward in the complex management 
of patients suspected of this disease. In this way diagnostic time, costs and potential 
complications from performing computed tomographic pulmonary angiography (CTPA) 
or ventilation-perfusion (V-Q) lung scintigraphy, including radiation exposure and al-
lergic reaction to contrast dye, are kept limited. 
The Wells rule (Table 1) is widely used as a clinical decision rule for the assessment of 
clinical probability for PE (1-5). Originally using this rule, patients could be divided into 
three categories of increasing risk for having PE. These categories were low (<2.0 points, 
2.0% PE), moderate (2.0-6.0 points, 18.8% PE) and high (>6.0 points, 50% PE) clinical 
probability.(5) It has previously been shown that anticoagulant therapy could be safely 
withheld from patients classified as low risk with a normal D-dimer concentration (28.4% 
of the population) (5). In a post hoc analysis, it was suggested that using dichotomiza-
tion of the Wells rule – dividing patients in to PE “unlikely” (≤4 points) and PE “likely” 
(>4 points) – PE might be safely excluded based on a low as well as an “unlikely” clinical 
probability and a normal D-dimer test, with very low three months venous thromboem-
bolism (VTE) recurrence (5). Importantly, in that study 50% of patients had a Wells score 
Table 1. The Wells clinical decision rule.5
Variable Points
Clinical signs and symptoms of DVT (minimum of leg swelling 3
and pain with palpation of the deep veins)
An alternative diagnosis is less likely than PE 3
Heart rate greater than 100 1.5
Immobilisation or surgery in the previous four weeks 1.5
Previous DVT/PE 1.5
Hemoptysis 1
Malignancy (on treatment, treated in the last 6 months or palliative) 1
clinical probability  




Likely  ≤ 4 total
Less likely > 4 total
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of 4 points or less (5.1% PE) compared to only 31% of patients who had a score of 2 points 
or less (2.0% PE). Thus, the 2-level approach increases the number of patients in whom 
radiological tests can be avoided although it puts more weight on the sensitivity of the 
D-dimer test. An additional advantage of the dichotomization of the Wells rule is that it 
involves a simpler triage in patients. 
In spite of the important advantages of a diagnostic strategy including the dichoto-
mized Wells rule and D-dimer testing to exclude acute PE, widely implementation of 
such a diagnostic algorithm is lacking (6). In one recent study, only 58% of the patients 
with a positive D-dimer underwent, as should be, CT-scanning, and in 7% of the patients 
with negative D-dimer results, superfluous CT scans were performed (7). One explana-
tion for this is that the safety of this algorithm is understudied and untreated PE is a 
major concern for every physician since that has been shown to have a high mortality 
rate ranging from 9.2-51% (8,9). 
For this reason, we have performed a systematic review and meta-analysis of studies 
in patients that excluded acute PE on the basis of an “unlikely” clinical probability (Wells 




A literature search was performed to locate all prospective studies using a diagnostic 
strategy including a dichotomized clinical decision rule and a D-dimer test to rule out 
PE. Predefined search terms were used as Mesh terms as well as free text words. All full 
articles published after the introduction of the Wells score (2000) till the December 1st 
2008 (date of our final search) were eligible for inclusion in the analysis. The articles 
were limited to the English, German, French or Dutch language. In addition to Medline, 
Embase and Cochrane databases were searched, but did not enclose any additional 
studies useful for inclusion in our meta-analysis. All patients with an “unlikely” clinical 
probability and normal D-dimer test result who did not undergo any further radiological 
imaging aimed at evaluating the presence of PE or DVT were included. Finally, a clinical 
follow-up of at least three months was demanded.
Study outcome
The outcome of this meta-analysis was the safety of not treating patients with suspected 
acute PE, an “unlikely” clinical probability according to the Wells rule (≤4 points) and a 
normal D-dimer test result. The primary study endpoint was defined as all objectively 
confirmed fatal and non-fatal VTE defined as PE or deep vein thrombosis (DVT). As a 
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secondary endpoint, we studied total VTE attributable mortality. Mandatory for inclu-
sion was the consecutive enrollment of patients and the prospective assessment of the 
Wells rule and D-dimer concentration. 
Data abstraction 
All identified articles were individually reviewed by two reviewers (S.P and F.K). In case of 
disagreement, a third reviewer (M.H.) was consulted. Data on the study design, patient 
characteristics, the incidence of PE or DVT in the follow-up period and the mortality 
rate attributable to PE were abstracted following the Guidelines proposed by the Meta-
analysis Of Observational Studies in Epidemiology (MOOSE) group (10). Individual study 
quality was assessed by the following items: patient enrollment, outcome assessment, 
duration of follow-up, loss-to-follow-up and funding source.
When studies were identified that excluded PE in patients based on an “unlikely” clini-
cal probability and a normal D-dimer test but the paper itself did not contain all neces-
sary information for our analysis, the authors of these papers were asked to provide the 
missing numbers. 
Statistical analysis
The proportions of total and fatal recurrent VTE in patients in whom acute PE was ruled 
out based were pooled to assess the safety of not treating these patients. Patients who 
were lost to follow-up were excluded from the analysis. For our primary endpoint analy-
sis, patients receiving anticoagulants and patients in whom additional diagnostic tests 
were performed despite both an “unlikely” clinical probability and a negative D-dimer 
were excluded. Since it is not unlikely that patients in whom additional tests were per-
formed despite formal exclusion of pulmonary embolism (which are protocol violations) 
are more prone to be diagnosed with a venous thrombotic event during follow-up, a 
second calculation of the incidence of the occurrence of thrombosis during follow-up 
was performed without excluding these patients, which leads to a more conservative 
estimation of the safety of this strategy. The upper limit of the 95% confidence interval 
of the fatal and non-fatal three months thromboembolic rate after a negative invasive 
pulmonary angiography was defined as the cut-off point for the safe exclusion of PE 
(11). To pool the proportions of venous thrombosis during follow-up, both random and 
fixed effect models were employed. Since the incidences of events were very low and 
even zero in some studies, individual studies by inverse variance weighting could not 
be pooled (using this strategy, studies with a proportion and a variance of zero would 
not be included in the model). Therefore inverse arcsine variance weights for the fixed 
effects model and DerSimonian-Laird weights for the random effects were used, (12) 
as embodied in the statistical package StatsDirect (StatsDirect Ltd, Cheshire, UK). To 
assess heterogeneity among included studies the I2 statistic with its 95% confidence 
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interval was calculated, which is the percentage of variation across studies that is due 
to heterogeneity rather than chance. All calculations were performed using StatsDirect 
(StatsDirect Ltd, Cheshire, UK).
RESULTS
Study selection
The literature search revealed 157 articles. Of these, 139 were excluded after review of the 
title and abstract. After full review another 14 articles were excluded because of use of 
other clinical decision rules, retrospective assessment of the Wells rule or performance 
of additional diagnostic tests to rule out PE. Eventually, 4 studies were approved for 
inclusion in this meta-analysis (figure 1)(1-4). 
Quali and characteristics of included studies
All four identified studies were prospective studies with a follow-up period of three 
months. The loss to follow-up was very low (0.0-0.7%, table 2). The mean age of the 
patients was in the range of 51 to 54 years (table 2) and 34.2 to 42.6% of the patients 










14 excluded after full text review
4 studies with negative D-
dimer and dichotomized
Wells Rule
figure 1. Flowchart of study inclusion
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between the studies, table 2). Different D-dimer tests were used; VIDAS D-dimer assay 
(BioMérieux, Marcy- l’Etoile, France) SimpliRED (Agen Biomedical Limited, Acaccia Ridge, 
Australia), Tinaquant assay (Roche Diagnostica, Mannheim, Germany) and the Accuclot 
latex agglutination D-dimer test (Sigma Diagnostics, St Louis, Mo). A total of 88 protocol 
violations (0-22% between the studies) were observed: in 45 patients, CT- or V-Q scans 
were performed to rule out PE although the assessment of clinical probability indicated 
“unlikely” and the D-dimer concentration was normal. Two of these 45 patients (3.3%) 
were diagnosed with PE and one (1.7%) received OAC therapy because of a medical his-
tory of acute PE and a clinical presentation of hemoptysis even though a subsequently 
performed CT-scan ruled out PE (3). In 14 additional patients undefined protocol viola-
tions were reported (1). Finally, 29 patients receiving anticoagulant therapy for other 
Table 2. Study characteristics
Study Rodger et al1,* van Belle et al2 Goekoop et al3 Anderson et al4,#
Characteristic
Study population 199 3306 879 NA
Age, mean (SD), y 53.5 (18) 53.0 (18.4) 51 (18) NA
Male 68 (34.2) 1409 (42.6) 329 (37.4) NA
History of VTE 22 (11.1) 480 (14.5) 83 (9.4) NA




29 (14.6) 610 (18.5) 50 (5.7) NA
Outpatients 141 (70.9) 2701 (81.7) 879 (100) NA
Duration of follow-up 3 months 3 months 3 months 3 months
Lost to follow-up 0 (0%) 4 (0.12%) 6 (0.7%) 0 (0%)
Study design Prospective Prospective Prospective Prospective






D-dimer cut-off value NA 500 ng/mL 500 ng/mL NA
Funding source The Heart and Stroke 







Institutes of Health 
research
* Only the Bioped arm is included since this arm contained the needed group of patients.
# Patient group was already excluded before characterisation 
$ SimpliRED (Agen Biomedical Limited, Acaccia Ridge, Australia)
† Accuclot latex agglutination D-dimer test (Sigma Diagnostics, St Louis, Mo)
‡ VIDAS D-dimer assay (BioMérieux, Marcy- l’Etoile, France) 
§ Tinaquant assay (Roche Diagnostica, Mannheim, Germany)ΔPatients underwent automated D-dimer test-
ing from plasma samples according to local practice in the participating 5 academic health centers
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reasons than PE were left out of the analysis in one study (2). In contrast to the former 59 
patients, follow-up in these 29 patients could not be retrieved. 
Meta-analysis
The 4 included studies comprised 5801 patients of who 1660 (29%) were left untreated 
because of unlikely clinical decision rule and normal D-dimer test result. Of these 1660 
patients 6 patients (6/1660, weighted pooled incidence 0.34%; 95%CI 0.036- 0.96%) were 
eventually diagnosed with symptomatic VTE during three months follow-up (Table 3, 
figure 2). One of these patients (1/1660, weighted pooled incidence 0.10%; 95%CI 0.0017-
0.46%) died possibly as a direct consequence of fatal PE (Table 3, figure 3). The pooled 
negative predictive value (NPV) of having VTE during three months follow up after an 
“unlikely” clinical probability in combination with a normal D-dimer test was 99.7% 
(95%CI 99.0-99.9%). 
After including patients in whom additional diagnostic tests were performed despite 
both an “unlikely” clinical probability and a negative D-dimer, the pooled analysis 
included 1719 patients of whom 8 were diagnosed with VTE during follow-up (8/1719, 
weighted pooled incidence 0.53%; 95%CI 0.24-0.92%). Of these, one patient (1/1719, 
weighted pooled incidence 0.096%; 95%CI 0.0008-0.42) was diagnosed with fatal PE. 
This results in a NPV of having VTE on follow-up of 99.5% (95%CI 99.1-99.8).The assess-
ment of heterogeneity in our primary analysis showed an I2 statistic of 46.2% (95%CI 
0-80.8%) in the VTE in follow-up analysis and an I2 statistic of 37.2% (95%CI 0-78.5%) in 
the mortality analysis. The use of a fixed effects model did not materially change the 
study outcome.
The possibility of publication bias in our meta-analysis was assessed with the use of 
funnel plots. No indication of publication bias was detected.
Table 3. Outcome of PE related morbidity and deaths of the included studies (3 months follow up)
Study Number of patients with “unlikely” 
clinical probability and negative 
d-dimer test (n)
Incidence of VTE 
in follow-up (n)
Number of mortality 
due to PE in follow 
up (n)
Rodger et al1 49 1 (%) 1 (%)
van Belle et al2 1028 5 (%) 0 (%)
Goekoop et al3 405 0 (%) 0 (%)
Anderson et al4 178 0 (%) 0 (%)
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0.0% (0.0-0.9%)
0.5% (0.2-1.1%)
2.0% (0.1-10.1%)Rodger et al1
van Belle et al2
Goekoop et al3




0.0% 3.0% 6.0% 9.0% 12.0%
0.3% (0.0-1.0%)
0.0% (0.0-2.1%)Anderson et al4
Incidence (%) total VTE in Follow-up
Combined
19.3%











0.0% 3.0% 6.0% 9.0% 12.0%
0.1% (0.0-0.5%)
0.0% (0.0-2.1%)
Incidence (%) total death due to PE
Anderson4 17.8%
Combined
figure 3. Incidence of death due to VTE on follow up (random effects model)
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DIScUSSION
The main finding of our study is that the pooled incidence of morbidity due to PE after 
an “unlikely” clinical decision rule (Wells Rule ≤ 4 points) in combination with a normal 
D-dimer test is 0.34% (95%CI 0.036- 0.96%), resulting in a NPV of 99.7% (95%CI 99.0-
99.9%). The upper limit of the 95% confidence interval of the three months VTE-rate 
after negative pulmonary angiography is 2.7% (11). Using this 2.7% as the threshold for 
the safe exclusion of PE, our analysis shows that ruling out PE on basis of a negative 
D-dimer test and an “unlikely” clinical decision rule is a very safe criterion even after in-
clusion of the patients in whom additional radiological tests were performed (weighted 
pooled incidence of VTE 0.53%). 
Additionally, the three months mortality risk of PE in these patients was very low 
(0.10%; 95%CI 0.002-0.46%). This pooled three months mortality rate compares favour-
able to the mortality rate after a negative pulmonary angiography (0.3%) (11).
The patients with “unlikely” clinical probability for PE and a normal D-dimer concentra-
tion represent almost one third of the total patient population with suspected acute PE. 
Importantly, CT scans can be withheld in all these patients, saving diagnostic time, costs 
and preventing CT related complications as contrast induced nephropathy or cancer 
caused by radiation exposure.
We consider our results representative because our results were based on a pooled 
analysis of a large cohort of 1660 patients. Given the extremely narrow confidence 
intervals we found, it is highly unlikely that future studies would materially change our 
results and influence the conclusions based on the present analysis. The data was ab-
stracted from high quality studies with a prospective design, consistent follow-up time 
and comparable demographic patient characteristics. Furthermore, all endpoints were 
well-defined and confirmed by predefined criteria. In addition, there was no indication 
for important inter-study heterogeneity since the I2 statistics for all analysis were rather 
low and the use of random or fixed effect models did not substantially alter our study 
outcome. We decided to present the results of the random effect models, since random 
effects models lead to more conservative estimates than fixed effect models. Therefore, 
underestimation of the incidence of VTE or death due to fatal PE is highly improbable. 
In addition, even after including patients in whom the study protocols were violated 
(i.e. additional diagnostic testing despite “unlikely” clinical probability and negative 
D-dimer) the incidences of morbidity and mortality due to recurrent disease remained 
very low. Furthermore, funnel plots provided no indication for the existence of publica-
tion bias. Of note, one potential limitation of our study is the use of different D-dimer 
assays among the included studies. Nonetheless, since all used assays are reported to 
have high sensitivity for detection of venous thromboembolism, we are convinced that 
this has not greatly influenced our study outcome.
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Our results have important clinical implications. The results of our meta-analysis show 
that anticoagulant therapy can safely be withheld without the need for any further 
radiological tests in patients with an “unlikely” CDR in combination with a normal D-
dimer test. These patients represent almost one third of the total patient population 
with suspected PE. It is possible to take fast management decisions by this combination 
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Contrast induced nephropathy (CIN) is a decrease in renal function following adminis-
tration of contrast media (CM) and is defined as an increase in serum creatinine over 25% 
or 44 μmol/ L from baseline in the absence of other causes. The aim of this meta-analysis 
was to asses the overall risk of CIN and the need for renal replacement therapy (RRT) 
after a contrast enhanced CT-scan. Finally, we aimed to identify subgroups at increased 
risk for CIN.
Methods
A literature search was performed to identify studies evaluating the incidence of CIN 
after contrast enhanced CT in Pubmed, Medline, Embase and Cochrane databases. Our 
primary endpoint was the pooled incidence of CIN. Secondary endpoint was the pooled 
incidence of CM induced need for RRT or chronic loss of kidney function after contrast 
enhanced CT. Furthermore, prespecified subgroup analyses were performed for different 
patient categories. Meta-analysis was performed using an exact likelihood approach.
Results 
In total, 40 studies evaluating the incidence of CIN after contrast enhanced CT were 
included in this meta-analysis. The pooled incidence of CIN after contrast enhanced CT 
was 6.3% (95% CI 4.9-8.1). The risk of RRT as a result of CIN was low, 0.06% (95% CI 0.008-
0.4) and the decline in renal function persisted in 1.1% of patients (95% CI 0.6-2.1%). The 
incidence of CIN was not influenced by study design or quality. Patients with chronic 
kidney disease (estimated filtration rate < 60 ml/min/1.73m2, incidence 7.7%, 95% CI 5.3-
11.1) or diabetes mellitus (incidence 10.5%, 95% CI 6.4-16.7) might be at slightly increased 
risk for the development of CIN after contrast enhanced CT.
conclusion
CIN occurs in about 6% of patients after contrast enhanced CT. In 1 % of all patients 
(95% CI 0.6-2.1%) the decline in renal function persisted. The clinical relevance of these 
findings should be elucidated in further studies on clinically relevant endpoints.
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INTRODUcTION
Contrast media are often administered intravenously to improve imaging in patients un-
dergoing CT-scanning. Besides allergic reactions, contrast induced nephropathy (CIN) is 
one of the most feared complications of iodinated contrast media (1). Contrast induced 
nephropathy is usually defined as an increase in serum creatinine over 25% or 44 μmol/L 
from baseline value in 48-72 hours after contrast media administration in the absence 
of other aetiologies (2,3). Although CIN is mostly mild and reversible, it can occasionally 
lead to a need for renal replacement therapy (RRT). Furthermore, after intra arterial con-
trast administration CIN, even in milder forms, is associated with an increased morbidity 
and mortality during hospitalization (3-5). 
Risk factors for the development of CIN have particularly been studied after intra arte-
rial contrast administration used for procedures like percutaneous transluminal (coro-
nary) angiography. Those risk factors such as diabetes mellitus, cardiovascular disease, 
use of nephrotoxic medication and chronic kidney disease are common in patients with 
an indication for contrast media enhanced CT-scanning. However, contrast enhanced CT 
might sometimes be withheld in patients at increased risk for developing CIN in order to 
prevent nephrotoxicity in patients with already multiple co-morbidities (6,7). This could 
result in a diagnostic delay or a reduced accuracy of the diagnostic process in a major 
group of patients (6,8). Therefore, detailed knowledge about the risk and the prevention 
of CIN is necessary (9). 
Various studies on the incidence and prevention of CIN have been performed over the 
last years and show an incidence of CIN after contrast enhanced CT varying between 
0-25 % (1,10). This wide variability could possibly be explained by the difference in co-
morbidities and the amount of contrast administered to perform contrast enhanced CT 
between the published studies. The aim of this meta-analysis was to assess the overall 
risk of CIN, persistent loss of renal function and the need for RRT in patients undergoing 
contrast enhanced CT. Finally, we aimed to identify subgroups at increased risk for CIN.
METHODS
Data sources and study selection
A literature search was performed to identify studies evaluating the incidence of CIN 
after contrast enhanced CT. Predefined search terms were used as Mesh terms and free 
text words, including “CIN”, “contrast media” and “venous”. Since the use of high osmolar 
contrast media decreased substantially after the year 2000, articles published thereafter 
till April 1st 2010 (date of final search) were eligible for inclusion in the analysis. The 
articles were limited to the English, Dutch, German and French language. In addition 
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to the Pubmed search, Medline, Embase and Cochrane databases were scrutinized, but 
did not enclose any additional studies eligible for inclusion. There were no restrictions 
to the included patient population. Finally, a follow-up period for the occurrence of CIN 
of at least 24 hours after contrast enhanced CT was demanded for studies to be eligible.
Study outcome
The main outcome of this meta-analysis was the pooled incidence of objectively con-
firmed occurrences of CIN after contrast enhanced CT. As a secondary endpoint, we as-
sessed the incidence of contrast media induced need for RRT. Furthermore, predefined 
subgroup analyses were performed for different patient categories at increased risk for 
CIN due to co-morbidities such as chronic kidney disease (estimated filtration rate < 60 
ml/min/1.73m2), diabetes mellitus and cardiovascular disease or the use of nephrotoxic 
medication. In addition a meta-regression was performed to estimate the effect of the 
administered CM dose and study quality on the occurrence of CIN. 
Data abstraction
All identified articles were reviewed independently by two reviewers (S.P. and J.K.). In 
case of disagreement a third reviewer (W.Z.) was consulted. Data on the study design, 
patient’s characteristics, the incidence of CIN in the follow-up period and the known risk 
factors for CIN were abstracted following the Guidelines proposed by the Meta-analysis 
Of Observational Studies in Epidemiology (MOOSE) group (11). When studies did assess 
the occurrence of CIN after contrast enhanced CT but the paper did not contain the 
necessary data for the analysis, the corresponding authors of the papers were contacted 
to provide the missing data. Individual study quality was assessed by an adaption of 
the Newcastle-Ottawa Scale (12). This scale contains among others data on the assess-
ment of exposure and outcome, timeframe, adequacy of follow up and demonstration 
of a stable renal function at start of the study, see table 2. First of all, the timeframe of 
follow up could be of major influence on the reported incidence of CIN. We considered 
a time frame of 24-96 hours after CT adequate. Second, when a large group of patients 
is lost to follow up, the observed incidence of CIN might not be accurate. Studies with 
at least 90% of patients with a complete follow up were considered ample. Third, if 
renal function is already declining prior to contrast enhanced CT, it might be difficult to 
establish whether a patient has developed CIN. For that reason, studies demonstrating 
renal function to be stable at baseline were regarded as sufficient. Fourth, studies were 
considered representative if the studied population comprised all patients undergoing 
CT in daily practice.
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Statistical analysis
The main outcome of the present meta-analysis was the pooled proportion of patients 
with CIN after contrast enhanced CT. For all studies, the proportion of patients with 
CIN was calculated as the number of patients with CIN divided by the total number of 
patients undergoing contrast enhanced CT. Exact 95% confidence intervals were calcu-
lated for all proportions. 
Meta-analysis was performed using an exact likelihood approach. The method 
used was a logistic regression with a random effect at the study level (13). Given the 
heterogeneity of clinical conditions, a random effects model was performed by default 
and no fixed effects analyses were performed. I2 statistics cannot be calculated from 
meta-analyses based on exact likelihood approaches, and I2 estimates were therefore 
not reported. For meta-analysis of proportions the exact likelihood approach based on 
a binomial distribution has advantages compared to a standard random effects model 
that are based on normal distributions (14). Firstly, estimates from a binomial model are 
less biased than estimates from models based on a normal approximation (13,15). This is 
especially the case for proportions that are close to 0 or 1. Secondly, no assumptions are 
needed for the exact approximation when dealing with zero-cells, whereas the standard 
approach needs to add an arbitrary value (often 0.5) which contributes to the biased 
estimate of the model (16,17). The meta-regression was based on a binomial distribution.
All analyses were performed with STATA 10.0 (Stata Corp, Texas, USA). 
RESULTS
Study selection 
The literature search identified 963 unique studies (figure 1). After evaluation of title and 
abstract 903 studies were excluded. Another 20 studies were excluded after more thor-
ough examination: eight of these 20 studies did not contain original data (5,18-24) and 
in five studies contrast media were administered intra arterially as well (23-27). Patients 
were included before the year 2000 in four studies and therefore were not eligible for 
inclusion (28-31). The endpoint of CIN was lacking in two studies (32,33). One study had a 
case control design so the incidence of CIN could not be determined (4). Finally, a total 
of 40 studies were eligible for inclusion in this meta-analysis. 
Study characteristics
Included studies were published between 2000 and 2010 and contained a total of 19,585 
patients, with the largest study comprising 11,516 patients (34). Serum creatinine was 
measured 48-96 hours after contrast enhanced CT in the majority of studies and in 7 
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cohorts after 48-168 hours. All included studies defined CIN as an increase in serum 
creatinine over 25% or over 44 μmol/ L (0.5 mg/dL) after contrast enhanced CT.
Study characteristics are summarized in table 1. Mean age ranged from 44-74 years 
old, the percentage of female gender varies from 3-58% and patients were administered 
between 10-230 ml of contrast media in concentrations of 200-400 mg/mL Iodine. In 
25 out of 33 studies (75%) including patients with chronic kidney disease, hydration 
prophylaxis regimes were advised. 
Table 1. Summary characteristics of 40 included studies
Study characteristics
Year of publication 2000 – 2010
Study design
Prospective follow-up study 21 (53%)
Retrospective follow-up study 19 (48%)
Studies including only high risk patients 
(i.e. eGFR < 60 ml/min/1.73m2)
16 (40%) •
Total number of patients 19 585
clinical characteristics
Mean age 58
Gender, m/f £ 10 992 / 7 963
Mean serum creatinine at baseline 
(μmol/L) 
102¥
Patients with chronic kidney disease* (%) § 35‡
Patients with diabetes mellitus (%) 28†
Patients with hypertension (%) 19§
Range of means NaCl or NaHCO3 ƒ administered (mL) 500-3000
Concentration Iodine in contrast media (mg/mL) 200-400 
Range of means of amount contrast administered (mL) 10-300#
Risk of bias assessment
Representativeness of the exposed cohort
 (% studies)
72.5 
Demonstration outcome of interest not present at start of study (% studies) 22.5
Adequate follow-up timeframe for outcomes to occur (% studies) 72.5
Adequacy of follow up of cohorts (% studies) 48
£ Data on 4 studies missing, ¥ Data on 8 studies missing, •data on 2 studies missing 
* eGfR: estimated glomerular filtration rate, ƒ Nacl: sodium chloride, NaHcO3: Sodium bicarbonate
§ chronic Kidney Disease, estimated glomerular filtration rate < 60 ml/min/1.73m2
‡ Data of 5 studies missing, † data of 17 studies missing, § data of 30 studies missing, # data on 11 
studies missing
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Study quality 
In 29 studies (73%) the cohort was representative for the population undergoing con-
trast enhanced CT in daily practice. In 29 (73%) studies the timeframe of follow-up was 
adequate for diagnosing CIN, between 24 and 96 hours after contrast enhanced CT. In 
other studies, serum creatinine was measured until one week after contrast enhanced 
CT. However, in only 18 studies (45%) follow up was completed in at least 90% of the 
included patients. Importantly, only nine studies (23 %) assured renal function to be 
stable at baseline, therefore a laboratory confirmed CIN would be unlikely to be due to 
an instable renal function. 
963 potentially relevant studies identified
and screened for eligibility
689 studies excluded after title evaluation
274 potentially relevant studies
214 studies excluded after abstract evaluation
60 potentially relevant studies
20 studies excluded after article evaluation
- 8 studies did not contain original data
- 5 studies included patients undergoing intra arterial
contrast administration as well
- 4 studies were performed before the year 2000
- 2 studies were missing the outcome of CIN
- 1 had a case control design
40 studies included
figure 1. Flowchart of study inclusion
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Meta-analysis
Reported incidences of CIN after contrast enhanced CT ranged from 0 to 25% (35,36). 
The weighted pooled incidence of CIN was 6.3% (95% CI 4.9-8.1) in a random-effects 
model (see figure 2). The need for RRT as a result of CIN was rare with a weighted pooled 
incidence of 0.06% (95% CI 0.01-0.4). Stratified analyses showed that only patients 
with chronic kidney disease or diabetes mellitus might be at slightly increased risk for 
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figure 2. Funnel plot of 40 included studies on the incidence of contrast induced nephropathy
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in patients with chronic kidney disease versus 5.5% (95% CI 3.2-9.2) in patients without 
chronic kidney disease and 10.5% (95% CI 6.4-16.7) in patients with diabetes mellitus 
versus 4.5% (95% exact CI 2.1-9.3) in patients without diabetes mellitus (see figure 3). 
Twenty studies reported the course of renal function in CIN positive patients at least one 
week after contrast enhanced CT, varying from one week till two months after contrast 
enhanced CT. In 1.1% of all patients undergoing CT (95% CI 0.6-2.1%) the decline in renal 
function persisted.
In a meta-regression the administered Iodine dose was not evidently associated with 
the occurrence of CIN (p=0.58). Restricting the analysis to studies with an adequate 
follow-up had no significant effect on the reported incidence of CIN. Neither had a 
random-effects meta-regression on the difference between prospective and retrospec-
tive studies (p=0.90) or the consecutiveness of included patients (p=0.73).
DIScUSSION
This is the first meta-analysis to assess the incidence of CIN after contrast enhanced CT. 
The main finding of this meta-analysis is a pooled incidence of CIN after contrast en-
hanced CT of 6.3%. In addition, the risk of RRT as a result of CIN after contrast enhanced 
CT was very low,(0.06%) and in 1% of all patients undergoing CT the decline in renal 
function persisted. Finally, patients with chronic kidney disease or diabetes mellitus 
seem to be at slightly increased risk for developing CIN after contrast enhanced CT.
There are some limitations as a result of the variable design of the studies included in 
our meta-analysis. First, it should be noticed that the incidence found in our study is 
probably an overestimation due to the following reasons; the definition of CIN requires 
absence of other aetiologies for the sudden rise in serum creatinine (2,3). If follow-up is 
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figure 3. Meta-analyses according to patient category
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underappreciated (6). Moreover, ten studies in this meta-analysis included patients who 
were admitted at an emergency department (7,10,18,37-43). Those patients might not 
be hemodynamically stable, which might lead to a, often clinically irrelevant, fluctua-
tion in serum creatinine values in the first days after admission which is independent of 
contrast enhanced CT. 
Second, the clinical course of CIN positive patients could not be studied by this meta-
analysis since only four out of the 40 included studies addressed hospitalization and 
morbidity after contrast enhanced CT and nine studies only addressed mortality as a 
secondary endpoint. In our opinion, further studies should all mention these items as 
an endpoint in their analysis. Furthermore, the 20 studies observing the course of renal 
function after patients were diagnosed with CIN had different timeframes for this end-
point, varying from one week to two months. It would be of great value when all studies 
could measure creatinine at various points in time. 
Third, not all studies reported risk factors for CIN detailed enough for proper subgroup 
analyses of our meta-analysis. As a result not all co-morbidities generally considered to 
be relevant risk for developing CIN, including heart failure and peripheral artery disease 
were shown to be risk factors according to this meta-analysis (9). Hence, only diabetes 
mellitus and chronic kidney disease were demonstrated to yield a slightly higher inci-
dence of CIN.
Fourth, we were unable to incorporate a control group. This control group might be 
able to indicate whether the risk of acute kidney injury is higher in patients receiving 
contrast media vs. patients undergoing CT without it. This might rule out the effect of 
other causes of acute kidney injury on the risk assessment of CIN. In studies includ-
ing patients in the emergency department or intensive care unit such a study design 
could make sense. However for studies reporting the incidence of CIN in an elective 
outpatient cohort, this control group would be of low relevance. We included four elec-
tive outpatient cohorts in our meta-analyses, reporting incidences of 1.8, 2.5, 4.1 and 
7.7% respectively (44-47). The profound evidence for CIN studied by a trial randomizing 
between the administration of contrast media or placebo will always be lacking due too 
the clinical indication for contrast administration. 
Additionally, our meta-analysis has some intrinsic limitations as well. First, our pooled 
incidence risk of CIN is influenced by preventive hydration regimes in patients at high 
risk for CIN. In 75% of studies including patients at high risk for CIN some form of hydra-
tion regime was applied. This might lead to an underestimation of the risk for CIN in 
high risk patients without preventive measures. Due to our design the magnitude of this 
effect on the incidence of CIN could not be assessed. No randomized controlled trials 
in patients undergoing contrast enhanced CT within our inclusion criteria for eligible 
studies were found. 
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Second, our meta-analyses might be under the influence of bias. Whether publication 
bias is present and what its influence might be on the effect estimate is difficult to estab-
lish. Observational studies on the incidence of CIN are less likely to lead to publication 
bias since studies reporting a relatively high or low incidence are both of interest for 
publication. Therefore if publication bias has occurred, it is not likely to be of strong 
influence on the incidence in our meta-analyses. 
Third, if the majority of trials in our meta-analyses only included patients at high risk 
for CIN, an overestimation of the incidence of CIN might be the result. In this analyses, 16 
out of 40 trials (40%) restricted the inclusion to patients at high risk for CIN, i.e. eGFR < 60 
ml/min/1.73m2, including 2,477 out of the total of 11,516 patients (22%). In daily practice, 
this proportion ranges from 10-39% (40,48). Furthermore, neither the consecutiveness of 
included patients nor study design had influence on the incidence of CIN. Therefore the 
effect of selection bias is most likely to be insignificant. 
However, we do regard our results as representative since they are based on pooled 
proportions in a total of 19,563 patients. Furthermore, the incidence of CIN had a small 
95% confidence interval, implying that the point estimate we showed is reliable. More-
over, the quality of individual studies did not clearly influence the incidence of CIN. 
Therefore, it is unlikely that bias as a result of low study quality influenced our results 
considerably. In addition, follow-up time for the assessment of CIN was consistent for 
the great majority of studies. Also, although the incidence of CIN in our meta-analysis 
might be under the influence of preventive hydration regimes, the incidence of CIN and 
the exceptional rare persistent decline in renal function indicate that contrast media can 
be safely administered to high risk patients when preventive measures are taken. 
Chronic kidney disease and diabetes mellitus are often describes as risk factors for 
CIN in literature (9,27,49,50). The higher incidence of CIN in patients with chronic kidney 
disease could very well be due to the definition of CIN which is defined by a rise in serum 
creatinine (6). In patients with a low glomerular filtration rate (GFR) serum creatinine 
rises more steeply when hemodynamic changes occur or contrast is administered (6). In 
order to prove a higher nephrotoxicity in patients with chronic kidney disease further 
studies should analyse the expression of markers for acute renal injury after contrast 
enhanced CT, such as neutrophil gelatinase associated lipocalin (NGAL) or kidney injury 
marker 1 (KIM-1) as shown by recent work (51,52). An explanation for this increased risk 
in patients with diabetes mellitus might be the result of a disturbed auto regulation 
in those patients (40,53,54). On the other hand, it is argued as well that patients with 
diabetes have a wider variability in serum creatinine which might lead to a spuriously 
higher incidence of CIN (6,36,55). 
Contrast induced nephropathy and the prevention of it in high risk patients is a dif-
ficulty in the diagnostic work up. Contrast enhanced CT is a frequently used diagnostic 
tool and the proportion of patients at high risk for CIN is increasing, due too the aging 
44 Chapter 3
of the population which is accompanied by chronic kidney disease and other co mor-
bidities. Contrast induced nephropathy preventing guidelines recommend hydration 
regiments in patients at high risk for CIN or even the use of a different, less accurate, 
diagnostic tool without contrast administration (56). This meta-analysis shows an inci-
dence of CIN of 6% with an incidence of RRT due to CIN of 0.06%. Moreover, in only 1% 
of all patients undergoing CT the decline in renal function persisted. Whether it is safe to 
perform contrast enhanced CT in high risk patients cannot be directly concluded from 
our results since most of the included studies involved some sort of protection measure 
against contrast nephropathy. 
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It has earlier been demonstrated that the time between symptom onset and objective 
diagnosis of pulmonary embolism (PE) does not influence outcome on re-thrombosis 
and mortality. This time frame consists of patient’s delay and doctor’s delay. It is un-
known whether this patient’s delay is of influence on the thromboembolic burden and 
right ventricular function. We sought to evaluate this by measuring Qanadli-score and 
RV/LV-ratio in PE patients with and without patient’s delay.
Methods
Post-hoc analyses of an observational prospective outcome study in 113 consecutive CT 
proven PE patients. In all patients Qanadli-score and RV/LV ratio were scored and dura-
tion from symptom onset until the clinical presentation was requested. Also mortality 
and hospital readmission in a 6-weeks follow-up period were collected.
Results 
Twenty patients with and 93 patients without delay, with identical baseline character-
istics and comorbidities, were included. In a linear analysis, Qanadli-scores were not 
correlated to delay with a R2 of 0.021 (p=0.130). RV/LV-ratio had a R2 <0.001 (p=0.991). 
Likewise, longer delay was not associated to 6-week mortality (Odds ratio: 0.65; 95%CI 
0.08-5.57) or hospital readmission (Odds ratio: 0.75; 95%CI 0.15-3.65). 
conclusion 
In our patient cohort, patient’s delay was not associated with higher thrombus load or 
right ventricular dysfunction. This could provide a possible explanation for the lack of 
association between delay in diagnosing PE and clinical outcome as found in earlier 
studies.
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INTRODUcTION
Acute pulmonary embolism (PE) is a frequently diagnosed disease with an incidence of 
1-2 per 1000 persons (1). Mortality rates range between 2-30%, depending on the size of 
the embolism and the cardiopulmonary condition of the patient (2). Especially in the 
first hours of the acute PE event, patients may die from PE (3). Nonetheless, in 17% of the 
patients PE is diagnosed more than a week after symptom onset (4). In recent studies no 
correlation was found between patient’s delay, defined as time between symptom onset 
and presentation at the hospital, and clinical outcome (5-7). In these studies it is hypoth-
esized that, from symptom onset until presentation, thrombus growth and aggravation 
of right ventricular function could be negligible in some patients (5-7). However, these 
studies were unable to confirm or reject this hypothesis.
The aim of present study was to investigate whether elevation of thrombotic burden 
and aggravated right ventricular function was irrespective of patient’s delay. This was 
done by measuring Qanadli-scores and RV/LV-ratio in 113 consecutive PE patients pre-
senting with and without delay. 
METHODS
Patients
This was a post-hoc analysis of an observational prospective outcome study conducted 
in an academic and a peripheral teaching-hospital, as described earlier (8-10). In short, 
during the period September 1st 2005 and December 1st 2008 all consecutive hemo-
dynamically stable in- and outpatients with a clinical suspicion for PE were eligible 
for inclusion. Patients with a likely clinical decision rule (Wells > 4 points total) and/
or an elevated D-dimer blood test (> 500 ng/mL) underwent a computed tomography 
pulmonary angiography (CTPA; Aquillion 64; Toshiba Medical Systems, Otaware, Japan). 
In patients with an unlikely clinical decision rule (Wells ≤ 4 points total) and a normal 
D-dimer blood test (≤ 500 ng/mL) PE was ruled out without further imaging (10). CTPA 
was considered positive for PE when at least one filling defect in the pulmonary artery 
tree was present. All patients with a clinical suspicion of PE, regardless of the outcome 
of the CTPA, were followed for a period of 6 weeks. Patients aged below 18 years, with 
impossibility to follow-up, hemodynamically unstable at presentation, pregnant, with 
known allergy to contrast agents, with renal impairment function and patients unable 
to give informed consent were excluded from this study. The study was approved by 
the Institutional Review Board of both participating hospitals and all patients provided 
written informed consent. 
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Radiological examinations
To quantify the vascular obstruction of the pulmonary arteries caused by PE, the scoring 
system as proposed by Qanadli et al. was used (12). In this score the left and right lung 
were regarded having 10 segmental arteries each (3 for the upper lobes, 2 for the middle 
lobe and to the lingula, and 5 for the lower lobes). Each individual segmental artery is 
scored 0 points when there is no thrombus present, 1 point for partial occlusion of the 
artery and 2 points for total occlusion. So, in total the maximal Qanadli-score was 40 per 
patient. Thrombi in the most proximal artery were scored a value equal to the number 
of segmental arteries present distally. Subsegmental PE was considered as a partial oc-
clusion and was assigned 1 point.
RV/LV-ratio was calculated by measuring the right and left ventricular dimensions on 
a post-processing workstation (Vitrea, version 2, Vital Images, Minnetonka, USA). This 
was done, as described earlier (13), in reconstructed CT-4 chamber view, by identifying 
the maximal distance between the ventricular endocardium and the interventricular 
septum, perpendicular to the ventricular long-axis. A RV/LV-ratio greater than 1.0 was 
considered as right ventricular enlargement.
Patient’s delay
Patient’s delay was defined as the time, expressed as number of days, between onset of 
symptoms and clinical presentation at the hospital. In case patients presented within 
24 hours of symptom onset, delay was scored in hours. Patient’s delay was scored at 
the day of presentation. In case patients had slowly progressing symptoms, the day the 
complaints started was scored as the onset of symptoms. If there were complains for a 
longer period with an acute change in symptoms, the acute moment was scored as the 
start of onset of symptoms.
Variables and study endpoints
The primary outcome of the study was the Qanadli-score and RV/LV-ratio relative to the 
duration of symptoms before presentation to the hospital. Secondary endpoints were 
mortality and hospital readmission 6 weeks after diagnosis of PE compared to patient’s 
delay for less and more than 7 days, as proposed in previous studies (5-7). In addition, 
subsegmental PE, a prior history of VTE and active malignancy were scored. 
Statistical analysis
Baseline patient characteristics are presented as mean ± standard deviation (SD). 
Qanadli-score, RV/LV-ratio and patient’s delays are presented as median with an inter-
quartile range (IQR). Nominal data are presented as N, %. Linear analysis was used for the 
analysis of correlations between delay and Qanadli-score and between delay and RV/
LV-ratio. For the correlation between delay and the secondary endpoints mortality and 
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hospital readmission, odds ratios with 95% confidence intervals (CI) were calculated. 
Because patients with massive PE are possibly more prone to present at the first or 
second day after symptom onset, our analyses could be biased. Therefore, all analyses 
were performed for a second time after excluding patients with a delay less than 2 days. 
Statistical analysis was performed using SPSS statistics 17.0.2 (SPSS Inc., Chicago, Illinois, 
The USA). P-values <0.05 were considered statistically significant.
RESULTS
PE was confirmed after CTPA in 113 of the 439 patients eligible for inclusion (25.7%). The 
baseline characteristics are depicted in table 1. Mean age was 56 ± 17 years. There were 
more male patients (60, 53.1%) than female patients (53, 46.9%; p<0.001), and more out-
patients (93, 82.3%) than inpatients (20, 17.7%; p<0.001). The amount of subsegmental PE 
did not significantly differ in patients with and without PE (p=0.706).
The median time from onset of symptoms to presentation was 2 days, IQR 1-6 days. In 
patients without PE (data not shown) median time from onset of symptoms to clinical 
presentation was identical (2 days, IQR 1-7 days). Patient’s delay of more than 7 days was 
present in 20 patients (17.7%) and 4 patients (3.5%) had a delay of more than a month. 
Forty-one patients (36.3%) presented within 24 hours of onset of complains of whom 23 










Age (years ± SD) 56 ± 17 55 ± 17 59 ± 17 0.322
Male sex (n,%) 60 (53.1) 53 (57.0) 7 (35.0) 0.075
Outpatients (n,%) 93 (82.3) 76 (81.7) 17 (85.0) 0.730
Previous VTE (n,%) 25 (22.1) 21 (22.6) 4 (20.0) 0.803
Malignancy (n,%) 24 (21.2) 20 (21.5) 4 (20.0) 0.883
COPD 7 (6.2) 4 (4.3) 3 (15.0) 0.073
Heart failure 5 (4.4) 4 (4.3) 1 (5.0) 0.892
D-dimer (ng/mL ± SD) 2770 ± 1678 2701 ± 1673 3090 ± 1706 0.350
Delay (days ± SD) 5.7 ± 9.2 2.4 ± 1.8 21.0 ± 13.4 <0.001
Qanadli-score (score ± SD) 12.3 ± 9.3 11.7 ± 9.5 14.6 ± 7.8 0.212
RV/LV-ratio (ratio ± SD) 1.09 ± 0.33 1.09 ± 0.35 1.09 ± 0.21 0.962
Subsegmental PE (n,%) 14 (12.4) 12 (12.9) 2 (10.0) 0.706
All-cause mortality (n,%) 8 (7.1) 7 (7.5) 1 (5.0) 0.693
Hospital re-admission (n,%) 14 (12.4) 12 (12.9) 2 (10.0) 0.706
SD, Standard Deviation; VTE, Venous Thromboembolic Event; COPD, Chronic Obstructive Pulmonary Dis-
ease; PE, Pulmonary Embolism
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(20.4%) within the first 12 hours. Twenty-one patients (18.6%) presented on the second 
day (Figure 1).
The median Qanadli-score was 10 points with an IQR of 4-21 points. The mean Qanadli-
score was 11.7 ± 9.5 in patients without delay and 14.6 ± 7.8 in patients with delay 
(p=0.212). When analyzed in a linear analysis, the Qanadli-score was not correlated to 
delay after symptom onset (R2 0.021 p=0.130 Figure 2a.). Likewise, in our second analysis 
after excluding patients presenting at the first 2 days after symptom onset, the Qanadli-
score was not associated with delay (R2 0.003, p=0.726 Figure 2b.). 
The median RV/LV-ratio was 1.02 with an IQR of 0.92-1.16. Mean RV/LV-ratio was 1.09 ± 
0.35 in patients without delay and 1.09 ± 0.21 in patients with delay (p=0.962). In a linear 
analysis, RV/LV-ratio did not correlate to patient’s delay (R2 <0.001 p=0.991 Figure 3a.). 
After excluding patients presenting at day 1 and 2 similar results were found (R2 0.002 
p=0.998 Figure 3b.)
Death after 6 weeks of follow-up occurred in 8 patients (7.1%) in which 7 out of 93 
without delay (7.5%) and 1 of 20 patients with delay (5.0%) died (Odds ratio: 0.65; 95% 
CI 0.08 – 5.6). A total of 14 out of 113 patients (12%) were readmitted to the hospital. In 
the group of patients with delay, 12 of 93 (13%) were readmitted and 2 of 20 patients 
(10%) with delay were readmitted to the hospital (Odds ratio: 0.75; 95% CI 0.15 – 3.6). 
Excluding the patients who presented within 48 hours of onset of symptoms or those 
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figure 1. Number of patients presenting per day delayed after symptom onset
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DIScUSSION
Our results show that the thromboembolic burden (assessed by the Qanadli-score) and 
right ventricular function (measured by the RV/LV-ratio on CT-scan) in patients diagnosed 
with acute symptomatic PE were not adversely affected in patients with a delay. Also, the 
6-weeks survival and hospital readmission rates are identical in patients with and with-
out patient’s delay. The latter findings correlate with earlier studies. One study showed 
that 3-month survival and recurrence VTE rates were not adversely affected by patient’s 
delay in 397 symptomatic PE patients presenting at the emergency ward. Seventy-two 
of these patients had patient’s delay of more than 7 days (18%). Deaths were identical in 
both groups (OR 0.9; 95% CI 0.4-2.0) (5). These results were confirmed by a second study, 















figure 2a. Scatter plot of the Qanadli-score and patients delay after symptom onset















figure 2b. Scatter plot of the Qanadli-score and patients delay in patients presenting after 2 days of symp-
tom onset
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in which 375 patients, admitted with the diagnosis of PE, were included. Patient’s delay 
of more than 7 days was present in 186 patients (50%). The primary outcome, mortality, 
was identical in patients with and without delay (6). A third retrospective study in 454 
consecutive PE patients, in which 113 patients (28%) were delayed more than a week, 
found that mortality was identical in patients with and without delay (7). However, none 
of these studies provided a pathophysiological explanation for these findings and all 
suggested further studying this observation. Our study strengthens the hypothesis by 
showing that, besides outcome on mortality and hospital readmission, also thrombo-
embolic burden was identical in patients with and without patient’s delay.
In an earlier study of our group, the predictive value of RVD and Qanadli-score on 
outcome during 3-months follow-up of patients with PE was evaluated (12). In that study, 
the RV/LV ratio and fatal PE related with a regression coefficient of 1.55 (p=0.04). PE 











figure 3a. Scatter plot of the RV/LV ratio and patients delay after symptom onset












figure 3b. Scatter plot of the RV/LV ratio and patients delay in patients presenting after 2 days of symptom 
onset
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patients with an obstruction index of 40%, 16 points or more which is the cut-off value 
as proposed by Qanadli (11), had an 11-fold risk of PE-related mortality than patients 
with an index smaller than 40% (13). Since our present study showed identical RV/LV 
ratios and Qanadli-scores in patients with and without patient’s delay, we assume that 
our data strengthens the hypothesis that patient’s delay does not influence outcome 
in patients presenting with PE. A previous study suggested that the lack of effect of 
delay on outcome might affect the guidelines that advise initial anticoagulant treatment 
before radiological examinations are performed (5). Although our data showed identical 
results regarding outcome on mortality and morbidity, only the effect of patients delay, 
time between symptom onset and presentation at the emergency ward, was studied. 
Withholding anticoagulant treatment before radiological examinations is doctors delay 
and has not been studied. Therefore we do not believe the results should affect current 
guidelines. 
Nonetheless, our thrombus loads are identical to those found in earlier studies using 
the Qanadli and/or Miller-index (11;14). An explanation could be the actual duration of 
the delay in our study, which was defined by reported time between the moment of 
symptom onset up to the moment of diagnosis. Notably, it is unknown whether the 
subjectively reported initial symptoms were actually caused by a PE. Another limitation 
to our study is that we only included hemodynamically stable patients who survived the 
first hours to undergo evaluation at the emergency ward. All these patients underwent 
a CT-scan based on an elevated Wells clinical decision rule and/or elevated D-dimer 
levels causing a selection bias in which only patients with multiple complains or patients 
with a certain degree of pulmonary artery obstruction were included. Therefore, the 
complaints and thromboembolic burden in patients with and without delay could be 
identical at the day of presentation in the hospital. However, there was a big interval in 
D-dimer levels indicating that our study population included both larger and smaller 
PE. It could also be debated that patients with patient’s delay had smaller PE at onset 
of symptoms and presented at the emergency ward after exacerbated symptoms due 
to thrombus growth. Still, the amount of subsegmental PE did not significantly differ 
between patients with and without patient’s delay. Finally, differences in patient charac-
teristics or VTE risk factors between patients with and without delay could also act as a 
confounder. However, the presence of active malignancy, COPD, congestive heart failure 
or a prior history of VTE was not different between the 2 study groups. 
 We conclude that both RV/LV ratio, and the arterial pulmonary obstruction assessed 
by the Qanadli-score, was identical in hemodynamic stable patients with and without 
patient’s delay. This strengthens the findings that PE-related mortality after a 6-week 
follow-up period was not related with patient’s delay. 
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Chapter 5 
NT-PRO-BNP levels in patients with 
acute pulmonary embolism are 
correlated to right but not left 
ventricular volume and function 
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NT-pro-BNP is primarily secreted by left ventricular (LV) stretch and wall tension. Notably, 
NT-pro-BNP is a prognostic marker in acute pulmonary embolism (PE), which primarily 
stresses the right ventricle (RV). We sought to evaluate the relative contribution of the 
RV to NT-pro-BNP levels during PE.
Methods
A post-hoc analysis of an observational prospective outcome study in 113 consecutive 
patients with CT proven PE and 226 patients in whom PE was clinically suspected but 
ruled out by CT. In all patients RV and LV function was established by assessing ECG-
triggered-CT measured ventricular end-diastolic-volumes and ejection fraction (EF). NT-
pro-BNP was assessed in all patients. The correlation between RV and LV end-diastolic-
volumes and systolic function was evaluated by multiple linear regression corrected for 
known confounders.
Results
In the PE cohort increased RVEF (β-coefficient (95%CI) -0.044(±-0.011); p<0.001) and 
higher RV end-diastolic-volume (β-coefficient 0.005(±0.001); p<0.001) were signifi-
cantly correlated to NT-pro-BNP, while no correlation was found with LVEF (β-coefficient 
0.005(±0.010); p=0.587) and LV end-diastolic-volume (-0.003(±0.002); p=0.074). In 
control patients without PE we found a strong correlation between NT-pro-BNP levels 
and LVEF (β-coefficient -0.027(±-0.006); p<0.001) although not LV end-diastolic-volume 
(β-coefficient 0.001 (±0.001); p=0.418). RVEF (β-coefficient -0.002(±-0.006); p=0.802) and 
RV end-diastolic-volume (β <0.001(±0.001); p=0.730) were not correlated in patients 
without PE. 
conclusion
In PE patients, lower RVEF and higher RV end-diastolic-volume were significantly 
correlated to NT-pro-BNP levels as compared to control patients without PE. These 
observations provide pathophysiological ground for the well known prognostic value 
of NT-pro-BNP in acute PE.
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INTRODUcTION
There are several methods to triage and assess the severity of acute pulmonary embo-
lism (PE). Probably the easiest method is by using a clinical decision rule, as the PESI 
score (1). Other means include the assessment of right ventricle function, by ultrasound 
or CT (2), or the measurement of biomarkers including troponin (3), D-dimer (4) and 
B-type Natriuretic Peptide (BNP) (5). 
BNP is an amino-peptide secreted as pre-pro-BNP by the myocytes in the left ventricle 
(LV) and right ventricle (RV). Elevated levels of BNP can cause a variety of physiological 
effects, including lowering of blood pressure, reducing peripheral vascular resistance 
and regulating sodium balance by influencing the renin-angiotensin-aldosteron system 
(6). These actions are thought to be beneficial in pathological states such as hyperten-
sion and compensated heart failure (7).
Since the RV has a relative thin wall compared to the LV, changes in BNP levels are 
mostly studied in conditions caused by hemodynamic changes in the LV (7). BNP levels 
are therefore well established markers for the prognosis and diagnosis of LV disease (8). 
Nonetheless, Tulevski et al. showed that BNP levels were also elevated in patients with 
acute PE when compared to healthy controls (9). This result was hypothesized by the 
authors to be caused by RV distress. It has additionally been shown that a low BNP level 
is a predictor for benign clinical outcome in patients with acute PE (10) and elevated BNP 
level a predictor for adverse clinical outcome (11). Another study showed that PE patients 
with RV enlargement had higher NT-pro-BNP and BNP levels (12). And it was shown that 
elevated NT-pro-BNP levels are a predictor of RV dysfunction in patients diagnosed with 
PE (13). In a recent meta-analysis it has been shown that elevated BNP predicts worse 
outcome of PE with an OR of 7.6 for 30-day mortality (5). These data reason that the 
increase of (NT-pro-)BNP levels in PE patients are caused by the relatively thin RV. How-
ever, to what extent elevation of BNP levels in PE patients are actually caused by the RV 
or LV distress is still unknown. Therefore we sought to evaluate the relative contribution 
of the RV and LV to NT-pro-BNP levels in patients with acute PE and compared it to the 
contribution of the RV and LV to NT-pro-BNP levels in PE negative patients. 
 METHODS
Patients
This was a post-hoc analysis of an observational prospective outcome study (14,15). 
Between September 1st 2005 and December 1st 2008 hemodynamically stable, con-
secutive in- and outpatients with clinically suspected acute PE and a strict indication for 
computed tomography pulmonary angiography (CTPA) were included. This indication 
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comprised patients with a likely clinical decision rule (Wells > 4 points total) and/or an 
elevated D-dimer blood test (>500 ng/mL). PE was ruled out in patients with an unlikely 
clinical decision rule and a normal D-dimer test without further imaging (16). All other 
patients underwent multi-detector row CTPA (Aquillion 64; Toshiba Medical Systems, 
Otawara, Japan) of the chest during breath-hold at inspiration (inter-observer agree-
ment 83% κ 0.85; intra-observer agreement 93% κ 0.87) (17). PE was considered present 
in case of at least one filling defect in the pulmonary artery tree. After the diagnostic 
CTPA, an ECG-synchronized dynamic cardiac CT was performed. Patients in whom PE 
was demonstrated were treated according to international guidelines with therapeutic 
doses of low molecular weight heparin for at least 5 days, and vitamin K antagonists for 
a minimum period of 3 months aiming at an INR of 2.0-3.0. In case of severe PE or clinical 
deterioration, admission to the intensive care unit and/or administration of thrombo-
lytic drugs was considered by the attending clinician. All patients who underwent CTPA, 
regardless of the outcome, were followed for a period of 6 weeks. Exclusion criteria were 
age below 18 years, impossibility of follow-up, hemodynamically instability at presen-
tation, pregnancy, patients with a known allergy to intravenous contrast media, renal 
function impairment and patients unable to give written informed consent. This study 
was approved by the Institutional Review Board of the two participating hospital and all 
patients provided written informed consent. PE was confirmed after CTPA in 113 of the 
439 patients eligible for inclusion (prevalence of PE 25,7%). To double match the number 
of PE patients, the first 226 consecutive patients in whom PE was ruled out were included 
for further analysis. Four patients with PE were excluded from the final analysis due to 
missing data (NT-pro-BNP in 3 patients and cardiac CT in 1 patient).
Image acquisition
Image acquisition was validated and described previously (18). In short, all patients 
received 35-40 mL of contrast agent in order to perform the low-dose ECG-synchronized 
cardiac CT scanning. The scan parameters were: tube voltage of 120 kV and tube current 
from 100 to 200 mA. Rotation time ranged between 0.4 and 0.5 seconds and pitch factor 
between 0.25-0.50. Both parameters were automatically determined based on the heart 
rate of each individual patient in order to obtain the best resolution. Radiation dose was 
determined with ImPACT CT Patient Dosimetry Calculator, version 1.0.2; ImpactSCAN; 
London, England [www.impactscan.org] and was an estimated 3.3 mSv. Image acquisi-
tion was done with a slice-thickness of 2 mm.
cardiac function
Ventricular volumes and function were assessed using dedicated cardiac function 
analysis software (CT-MASS; Medical Imaging Systems, Leiden, The Netherlands) as 
previously described (15). First, the phases with the largest and the smallest RV volumes 
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were selected using running cine movies on the midventricular level. These selections 
represented the end-diastolic and end-systolic phases. The endocardial borders for the 
RV and LV were drawn in every other transverse section, from apex to the level of the 
pulmonary outflow tract, in the end-diastolic and end-systolic phase. Out of these draw-
ings, RV and LV end-diastolic volume (RV inter-observer variability 1.0%, intra-observer 
variability 0.8%; LV inter-observer variability 2.3%, intra-observer variability 1.0%), end-
systolic volume (RV inter-observer variability 1.8%, intra-observer variability 0.9%; LV 
inter-observer variability 3.8%, intra-observer variability 1.3%), stroke volume (RV inter-
observer variability 3.1%, intra-observer variability 1.8%; LV inter-observer variability 
4.4%, intra-observer variability 2.1%) and ejection fraction (RV inter-observer variability 
3.1%, intra-observer variability 1.8%; LV inter-observer variability 4.4%, intra-observer 
variability 1.3%) were calculated (15;19). Threshold values were RVEF ≤47%; LVEF ≤57%; 
RVEDV ≥227mL for males and ≥154mL for females; LVEDV ≥195mL for males and ≥141mL 
for females (20).
Blood sampling
Venous plasma and serum samples were obtained at admission and immediately stored 
at -80 °C. After inclusion of all patients, samples were analyzed after a single thaw. NT-
pro-BNP levels were measured with a quantitative immunoassay (Elecsys 2010 analyzer, 
Roche Diagnostics, Mannheim, Germany). The claimed CV’s by the manufacturer at con-
centrations above 70 pg/mL is below 4% for intra-assay precision and below 5% for inter-
assay precision. Functional sensitivity (lowest concentration measured with inter-assay 
precision of 20% CV) was measured at 10 pg/mL. Both the cardiac CT-measurements 
and the NT-pro-BNP level assessment were performed post-hoc by different researchers 
blinded for clinical information.
Statistical analysis
For all baseline characteristics, data are presented as mean ± standard deviation (SD). 
NT-pro-BNP is presented as median with an interquartile range (IQR). Since NT-pro-BNP 
levels were not normally distributed, they were Log-transformed. Receiver operat-
ing characteristic (ROC)-curve was used to analyze at which NT-pro-BNP level RV/LV 
ratio starts to be abnormal. Two multiple linear regressions were used to assess the 
relation between log NT-pro-BNP measurements and cardiac function. Data is given 
as β-coefficient ± SE which reflects the difference in log NT-pro-BNP associated with 
a difference of 1 unit of SD. P values <0.05 were considered significant. Non significant 
p-values are referred as ‘ns’. In model 1, the association of the RVEF and LVEF and RV and 
LV end-diastolic volumes and log NT-pro-BNP was evaluated. This model was corrected 
for known risk factors causing elevation of NT-pro-BNP, which are age, sex and creatinine 
clearance. In addition, RV and LV end-diastolic volume were included as covariates in 
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this model. Since the EF is calculated by dividing the stroke volume by the end-diastolic 
volume, a second model for the association of the RV and LV end diastolic volume and 
log NT-pro-BNP was sought. Model 2 was corrected for age, gender and creatinine clear-
ance. Statistical analysis was done using SPSS statistics 17.0.2 (SPSS Inc., Chicago, Illinois, 
The USA) 
RESULTS
The baseline characteristics of the study participants are depicted in table 1. The mean 
age was 56 years in the patients with PE and 55 years in patients without PE (p=0.707). 
In the patients with acute PE, 54% were male compared to 44% in the patients without 
PE (p=0.071). A history of previous venous thromboembolic events (VTE) was present 
in 23% of the patients with PE and in 13% of the patients without PE (OR 1.95, 95% CI 
1.08-3.52). COPD was more frequent in the patients without PE (6% vs. 16%, OR 0.35, 
95% CI 0.14-0.78). Active malignancy (23% vs. 25%, p=0.710) and left sided heart failure 
(4.6% vs. 7.5%, p=0.176) were equally distributed between both groups. Mean systolic 
Table 1. Baseline patient characteristics
Variable
Patients with PE 
(N=109)




Age (years ± SD) 56 ± 16 55 ± 17 0.707
Male sex (n, %) 59 (54) 99 (44) 0.071
Previous VTE (n, %) 25 (23) 30 (13) 0.024
Active malignancy (n, %) 23 (21) 52 (23) 0.710
COPD (n, %) 7 (6) 37 (16) 0.012
Left sided heart failure (n, %) 4 (3,7) 17 (7,5) 0.176
Inpatient (n, %) 19 (17) 58 (26) 0.097
NT-pro-BNP > 600 pg/mL (n,%) 31 (28) 56 (25) 0.460
Creatinine clearance (mL/min/1.73m2 ± SD) 87 (29) 93 (53) 0.234
Systolic blood pressure (mmHg ± SD) 139.1 (17.2) 137.5 (21.5) 0.610
Diastolic blood pressure (mmHg ± SD) 78.7 (12.2) 76.8 (12.5) 0.356
Heart rate (BPM ± SD) 89.9 (18.6) 84.4 (16.7) 0.066
LV ejection fraction (%± SD) 52.7 (9.3) 54.0 (12) 0.312
RV ejection fraction (%± SD) 45.2 (12) 50.5 (10) <0.001
LV end diastolic volume (mL ± SD) 154 (49) 155 (49) 0.789
RV end diastolic volume (mL ± SD) 190 (61) 167 (61) 0.002
PE indicates pulmonary embolism; SD, standard deviation; VTE, venous thromboembolic event; COPD, 
chronic obstructive pulmonary disease; BPM, beats per minute; LV indicates left ventricular; RV, right ven-
tricular
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blood pressure was 139.1 mmHg in PE patients and 137.5 mmHg in patients without PE 
(p=0.610), diastolic blood pressure was 78.7 in PE patients and 76.8 in patients without 
PE (p=0.356) and heart rate was 89.9 beats per minutes (BPM) in patient with PE and 84.4 
BPM in patients without PE (p=0.066).
NT-pro-BNP level >600 pg/mL, which has a high discriminative power as predictor 
for adverse clinical events after PE (14), was present in 28% of the patients with PE and 
in 25% of the patients without PE (p=0.460). In patients with PE the median NT-pro-
BNP level was 223.0 pg/ml with an IQR of 54.9-1021.5 pg/ml. In patients without PE the 
median NT-pro-BNP level was 146.4 with an IQR of 53.2-598.6 (p=0.230).The RVEF was 
significantly lower in patients with PE than in those without PE (45.2% ± 12 vs. 50.5% ± 
10; p<0.001) and 50 PE patients (46%) had abnormal RVEF while in the patients without 
PE only 62 (27%) had abnormal RVEF (p<0.001). In addition, RV end-diastolic volume was 
significantly larger in the PE patients (190 mL ± 61 vs. 167 mL ± 61 p=0.002) and in 49 PE 
patients (45%) RV end-diastolic volume was abnormal versus 66 patients (29%) without 
PE (p=0.005). LVEF (p=0.312) and LV end-diastolic volume (p=0.789) did not significantly 
differ between the 2 patient cohorts. The 77 (out of 336) patients with pathological car-
diac function had significantly higher NT-pro-BNP values compared to patients with 
normal ventricular function (210 vs. 156 pg/mL, p<0.001). ROC-curve showed that RV/
LV ratio started to be abnormal at 180 pg/mL (sensitivity 67.5%; specificity 57.0%). At the 
cut-off point of 600 pg/mL sensitivity was 42.9% and specificity 79.0%.
With regard to the first multiple linear regression (table 2), the RV and LVEF were 
related with log NT-pro-BNP. In an age-, sex-, creatinine clearance- and end-diastolic 
volume-adjusted model, a decreased RVEF was significantly associated to increased 
NT-pro-BNP levels in patients with PE. Every percent increase of the RVEF caused a rise 
of log NT-pro-BNP with β-coefficient -0.044 ± -0.011 (p<0.001). A change in LVEF was 
Table 2. Association of right- and left ventricular ejection fractions with log NT-pro-BNP








RV ejection fraction (%) -0.044 -0.011 <0.001 -0.002 -0.006 0.802
LV ejection fraction (%) 0.005 -0.010 0.587 -0.027 -0.006 <0.001
Age (years) 0.021 0.004 <0.001 0.016 0.003 <0.001
Sex (being female) 0.551 0.138 <0.001 0.097 0.096 0.310
eGFR (mL/min/1.73m2) 0.002 0.002 0.488 -0.001 0.001 0.146
RV end diastolic volume (mL) -0.001 0.002 0.522 0.001 0.001 0.274
LV end diastolic volume (mL) 0.003 0.002 0.145 -0.001 0.001 0.451
RV indicates right ventricular; LV, left ventricular; eGFR, estimated glomerular filtration rate
† β-coefficient reflects the difference in log NT-pro-BNP associated with a difference of 1 unit of SD, for 
example, for each SD unit higher RV ejection fraction, log NT-pro-BNP is higher by β.
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not significantly correlated to NT-pro-BNP levels (β-coefficient 0.005 ± 0.010; p=0.587). In 
contrast, NT-pro-BNP levels in patients without acute PE were not dependent on RVEF 
(β-coefficient -0.002 ± -0.006; p=0.802) but strongly correlated to LVEF (β-coefficient 
-0.027 ±0.006; p<0.001). Also increasing age (β-coefficient 0.021 ± 0.004; p<0.001) and 
being female (β-coefficient 0.551 ± 0.138; p<0.001) significantly influenced the log NT-
pro-BNP levels in patients with PE. In patients without PE only age had a significant 
contribution (β-coefficient 0.016 ± 0.003; <0.001). Being female did not contribute 
significantly. This could be explained by the significantly higher age and both RV and 
LV end-diastolic volumes in male patients in the PE negative patients (data not shown).
In the second multiple linear regression (table 3), EF was taken out of the model. In 
latter model, RV and LV end diastolic volumes were related to log NT-pro-BNP levels. In 
an age-, sex- and creatinine clearance-adjusted model, a decrease in RV end diastolic 
volume significantly increased NT-pro-BNP levels (β-coefficient 0.005 ± 0.001; p<0.001) in 
patients with PE while LV end diastolic volume did not significantly influence log NT-pro-
BNP levels (β-coefficient -0.003 ± -0.002; p=0.074). Also an increase in age significantly 
raised log NT-pro-BNP (β-coefficient 0.024 ± 0.005; <0.001). In patients without PE on the 
other hand, LV (β-coefficient 0.001 ± -0.001; p=0.418) and RV (β <0.001 ± -0.001; p=0.730) 
end diastolic volumes were not associated to NT-pro-BNP levels. Increase in age, like in 
all analysis before, contributed significantly to a change in log NT-pro-BNP (β-coefficient 
0.018 ± 0.003; <0.001).
DIScUSSION
This study assessed the relative contribution of the right and left ventricle to NT-pro-BNP 
levels in the setting of patients with acute PE. Our results indicate that NT-pro-BNP levels 
in PE patients were strongly correlated with RVEF but not with LVEF and volume in PE 
patients. In patients in whom PE was suspected but ruled out by CTPA, the opposite was 
Table 3. Association of right- and left ventricular end-diastolic volumes with log NT-pro-BNP








RV end diastolic volume (mL) 0.005 0.001 <0.001 <0.001 0.001 0.730
LV end diastolic volume (mL) -0.003 0.002 0.074 0.001 0.001 0.418
Age (years) 0.024 0.005 <0.001 0.018 0.003 <0.001
Sex (being female) 0.455 0.157 0.004 0.010 0.105 0.922
eGFR (mL/min/1.73m2) 0.001 0.003 0.734 -0.001 0.001 0.113
RV indicates right ventricular; LV, left ventricular; eGFR, estimated glomerular filtration rate
† β-coefficient reflects the difference in log NT-pro-BNP associated with a difference of 1 unit of SD, for ex-
ample, for each SD unit higher RV end diastolic volume, log NT-pro-BNP is higher by β.
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shown: in these patients a decrease in LVEF was significantly associated with elevated 
NT-pro-BNP levels, while RVEF and RV and LV end-diastolic volumes were not.
In a previous study in 50 patients with PE presented at the emergency ward of a Uni-
versity hospital, it was already suggested that a rise in NT-pro-BNP already occurs before 
the rise of cardiac damage-related biomarkers (12). NT-pro-BNP is therefore, possibly, 
a biomarker released in an early stage of pulmonary embolism-associated myocardial 
stretch. This was confirmed in a second study in 77 PE patients, which found a similar 
correlation between NT-pro-BNP and right ventricular enlargement (13). Our study sup-
ports the hypothesis that elevated NT-pro-BNP levels are caused in an early stage by 
mechanical stress of the RV in acute PE patients, and not or in a far lesser extent to 
LV hemodynamics. In comparison with the 2 studies mentioned above, we included all 
in- and out-hospital patients with suspicion of PE and were therefore able to compare 
patients with PE to patients in whom PE was expected but ruled out on CTPA. Our obser-
vations are also in line with similar findings in other pathological conditions leading to 
RV overload, such as in pulmonary hypertension, although this represents chronic and 
not acute RV overload with pathophysiological thickening of the RV wall. In this condi-
tion BNP levels have been shown to correlate with RV remodeling, severity of pulmonary 
hypertension and prognosis (21-24).
The clinical use of NT-pro-BNP level assessment in acute PE has been studied in recent 
years. Several studies have shown that because of the benign prognosis of PE associated 
with low NT-pro-BNP levels, patients can be safely treated in an out-of-hospital setting 
(25). A prospective outcome study has indicated that NT-pro-BNP levels, as compared 
to several biomarkers including troponin and D-dimer, as well as ventricular function 
measurement, had superior accuracy and clinical utility for identification of PE patients 
with low risk of adverse events (14). This was also shown in a recent study that measured 
the negative predictive value of the Pulmonary Severity Index (PESI) (26) and compared 
it to NT-pro-BNP levels. A PESI score with a cut-off of 86 (NPV 88%) points was inferior to 
a NT-pro-BNP below 300 pg/mL (NPV 100%) (27). 
Our study has some limitations. First, we only included 113 patients with PE in our 
study. Due to this relatively limited amount of PE patients our study and observations 
are prone to unmeasured confounders. However, previous studies correlating NT-pro-
BNP with right ventricular enlargement and dysfunction were done in 50 and 77 PE 
patients. Therefore we assumed we had a reasonable amount of patients. Furthermore, 
we did not include all patients in whom PE was ruled out on CTPA. Nonetheless, by 
using the first 226 consecutive patients without PE we consider our selected group 
representative for the entire population. Third, mean NT-pro-BNP levels are identical 
in patients with and without PE. We believe this is caused by other cardiopulmonary 
morbidities, like heart failure and COPD, which were more commonly present in patients 
without PE. Fourth, ECG-synchronized cardiac CT scanning was performed to assess RV 
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and LV function while MRI is considered as the golden standard. However, recent stud-
ies have shown that ECG-synchronized cardiac CT scanning and MRI give comparable 
accuracy and reproducibility in assessing the cardiac ventricles (28;29). Unfortunately, 
these studies were all performed in healthy patients without the acute condition of PE. 
In these patients heart rate was normal and regular. To prevail this fact, we excluded all 
unstable patients. Furthermore, none of the patients had irregular heartbeats. Therefore 
we assumed cardiac CT to be sufficiently accurate and reproducible and comparable to 
cardiac MRI. Fifth, we did not measure pulmonary artery pressure, which is the patho-
physiological link between PE and RV enlargement and dysfunction. However, we do not 
assume that the pulmonary artery pressure will influence the correlation of NT-pro-BNP 
and RV function. At last, we used a cut-off point for NT-pro-BNP of 600 pg/mL. This cut-
off point was, in a previous study in this population (14), found to have a high sensitivity 
(90%, 95% CI 56-99.8) and specificity (78%, 95% CI 70-84) for adverse clinical outcome. 
However, the cut-off point of NT-pro-BNP is not well assessed and varies between 300 to 
1000 pg/mL in current literature (30-32)
In summary, our data show that in patients with hemodynamically stable PE, lower 
RVEF and higher RV end-diastolic-volume were significantly correlated to NT-pro-BNP 
levels as compared to control patients without PE. These observations provide patho-
physiological ground for the well known prognostic value of NT-pro-BNP in acute PE.
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Data relating blood pressure class to subclinical organ damage are infrequently re-
ported in populations with a traditional ‘non western’ lifestyle. As the relevance of blood 
pressure stratification to cardiovascular prognosis has not been elucidated in these 
low-income countries at the second epidemiological transition, we aimed to study the 
effect of blood pressure class on carotid artery intima-media-thickness (IMT) on Flores 
Island, Indonesia.
Methods
 A cross-sectional study was performed in 476 inhabitants (male/female) of Flores. Blood 
pressure was classified using the ESH/ESC classification. The primary endpoint was mean 
carotid-IMT measured by ultrasonography in classes of blood pressure. Covariate analy-
sis was performed adjusting for conventional cardiovascular risk factors.
Results
Blood pressure ranged from 94-250 mmHg systolic and 50-125 mmHg diastolic, 35% of 
the population had “Grade-I-hypertension” or higher, 1,7% of the population was short-
term treated with antihypertensive therapy. IMT significantly differed for blood pressure 
classes (p<0.001). Mean(±SEM) IMT was 587.8(±9.3)µm, 621.5(±7.6)µm, 653.6(±10.5)µm, 
717.9(±14.0)µm, and 750.1(±21.8)µm for “optimal”, “(high) normal”, “grade-I, grade-II and 
grade-III-hypertension” classes, respectively. After adjustment for cardiovascular risk 
factors, similar results were obtained.
conclusions 
A strong association was found between blood pressure class and carotid artery intima 
media thickness in treatment naïve subjects of a population with a traditional lifestyle, 
at the second epidemiological transition. Intriguingly, the increase of intima media 
thickness was already observed at the “high normal” BP class. This study may help to 
prioritize preventive and therapeutic measures to lower blood pressure in countries at 
the second epidemiological transition.
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INTRODUcTION
Eighty percent of global cardiovascular mortality occurs in low and middle income coun-
tries (1). Bibliographic studies looking at global burden of diseases, have reported that 
hypertension is the leading cardiovascular risk factor (2) with a modeled estimate of 639 
million hypertensive adults in the year 2000 in economically developing countries(3). 
The main cause of mortality defines the stage of epidemiological transition. Before the 
first epidemiological transition death was mostly due to war and accidents/injuries. 
During the second epidemiological transition mortality is mainly characterized by a 
high burden of infectious disease, degenerative and man-inflicted diseases are slowly 
emerging. During the third epidemiological transition, cardiovascular mortality replaces 
infectious diseases as the primary cause of death. Many low income countries are at 
the second stage of epidemiological transition (4). The island of Flores, Indonesia, is 
regarded to be at this stage, nevertheless besides infectious diseases, cardiovascular 
disease and elevated blood pressure are becoming important causes of visits to health 
centers (5). Subjects living at Flores Island have little exposure to “Western type risk fac-
tors”. In addition, access to antihypertensive medication and statins is very limited. 
Blood pressure is an established and important risk factor for cardiovascular disease. 
Blood pressure can be classified in stages. These stages or classes are related to car-
diovascular prognosis (6). In high income countries, Stamler et al showed that “Grade II 
hypertension” is associated with an adjusted relative risk of 4.57 for coronary heart mor-
tality if compared to subjects in the “optimal” blood pressure class (7). A Finnish study 
described the relation between blood pressure classes and echographically measured 
carotid artery intima media thickness, an established intermediate marker of athero-
sclerosis (8-10). The relevance of blood pressure classes with respect to subclinical organ 
damage has not been assessed in low income countries at the second epidemiological 
transition. Carotid artery intima media thickness is listed as a measure of subclinical 
organ damage in the guidelines of hypertension (6). If blood pressure is a universal risk 
factor it is to be expected that a higher blood pressure class results in higher carotid 
artery intima media measures also in low income countries at secondary transition.
It is conceivable that currently available data may underestimate the effect of blood 
pressure class on carotid artery intima media thickness due to the high level of care 
given to patients either in the primary or secondary prevention setting in high and 
middle income countries. In this respect, studies in treatment naïve populations may 
add valuable information. We hypothesize that blood pressure class defines carotid 
artery intima media thickness in a population with a traditional “non-western” life style 
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at the secondary epidemiological transition. Therefore, we studied carotid artery intima 
media thickness in relation to blood pressure class in a nearly treatment naïve popula-
tion on Flores Island, Indonesia.
METHODS
Study area on flores Island, Indonesia
Flores Island, East Indonesia, is one of the Lesser Sunda Islands with a surface area of 
17,164 sq km. In Nangapanda, Ende District, a rural area in the mid-South of Flores, which 
is the study area, the inhabitants follow a traditional lifestyle, the main sources of income 
being labor-intensive agriculture, unassisted by mechanical tools, decorative stone col-
lecting and sarong weaving. The diet mainly consists of the freshly grown vegetables 
and fresh fish. The fish is brined to preserve and stored for times of scarcity hereby 
becoming the most important source of salt intake. Coconut oil and fresh coconut milk 
are used for frying and cooking. (Information derived of local sources, questionnaires 
administered during the surveys and from “The official site of Ende District, East Nusa 
Tenggara. www.endekab.go.id 20-04-2010”).
Study population and design
All included patients were participants of the ImmunoSPIN project. The ImmunoSPIN 
project (www.immunospin.org) was established in Nangapanda area, which has been 
described in detail before (11). The ImmunoSPIN project was approved by the Research 
Ethical Committee of the University of Indonesia, Jakarta, Indonesia. Because of the high 
rate of illiteracy amongst patients, verbal informed consent was obtained from each 
subject. A total of 500 randomly selected inhabitants of Nangapanda, between the age 
of 18 and 80 years, were invited for carotid artery IMT measurements on ten in advance 
specified days in July 2009. Patients were selected based on their address. By choosing 10 
research days all parts of the village were covered and therefore the group is representa-
tive for the inhabitants of Nangapanda. Of the 500 invited patients, 476 (95.2%) accepted 
the invitation. Here, we describe the results of a cross sectional observational study. The 
primary aim of the study was to study the effect of blood pressure class on carotid artery 
intima media thickness in an environment at the secondary epidemiological transition, 
unaffected by conventional “Western-type cardiovascular risk factors” and unbiased by 
cardiovascular treatment on Flores Island, Indonesia.
clinical data
Interviews were performed for medical history, family history, medication and cigarette 
smoking. Medical past and family history were categorized in cardiac events, hyperten-
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sion, cerebrovascular events and diabetes mellitus type II. Age estimates were derived 
from interviews and missionary records. In case age was unknown, age estimates were 
done using a collection of information gathered from birth related events, neighbours, 
relatives, or from calculations derived out of their children’s age. Waist hip ratio (WHR) 
and body-mass index (BMI) were measured in all patients. In all patients the Systematic 
Coronary Risk Evaluation (SCORE)-score was calculated. Since Flores is considered a low 
risk population, the low risk SCORE-chart of Southern Europe was used. In order to 
calculate a SCORE-score in all individual patients, even below the age of 40 and above 
the age of 65, all patients were extrapolated to the age of 60, as proposed in the original 
ESH/ESC guidelines (12). 
Blood pressure measurement
Blood pressure measurements were taken of all patients in supine position after a 5 min-
ute rest. Measurements were done 3 consecutive times on the left arm in all patients us-
ing a digital sphygmomanometer from Omron 705IT (HEM-759P-E2) (OMRON Healthcare 
Europe BV, The Netherlands). The average of three systolic and diastolic blood pressure 
measurements was used in the analysis. The mean blood pressures were grouped using 
the criteria published by The European Society of Hypertension (ESH) and The European 
Society of Cardiology (ESC) 2007 classification for adults above 18 years of age. (6) “Opti-
mal” blood pressure was a blood pressure <120/80 mmHg, “(high) normal” is defined as a 
blood pressure of ≥120/80 mmHg and lower than 140/90 mmHg, “grade I hypertension” 
as ≥140/90 mmHg and lower than 160/100 mmHg, “grade II hypertension” as ≥160/100 
mmHg and lower than 180/110 mmHg and grade III hypertension as a blood pressure 
≥180/110 mmHg.
carotid artery intima media thickness measurement 
IMT was measured while the patient was lying in a supine position. Measurements were 
conducted at 3 different angles of both the right and left common carotid artery at 
10 mm proximal of the carotid artery bulb after shipping a mobile ultrasound device 
(Mylab®25 ultrasound system with a LA523 13-4MHz transducer, ESAOTE, S.p.A, The Neth-
erlands) from the Netherlands to Flores Island. The mean of these 6 measurements was 
used in the analysis. First, a pilot study on 46 randomly chosen patients was performed 
in order to evaluate the quality and reproducibility of the measurements and to evaluate 
the infrastructure. These IMT measurements were done twice by 2 trained ultrasonog-
raphists (LJW and AEW) after training under supervision (of JTT) at the vascular and 
internal medicine outpatients-ward at Leiden University Medical Centrum (LUMC), The 
Netherlands. A highly significant correlation was observed between both echographists 
with a Pearson’s coefficient (r) of 0.933. A Bland-Altman plot (not shown) showed no 
significant difference between both echographists. An acceptable variance around the 
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mean (within 1.96 standard deviations) was observed without downward or upward 
bias. The IMT measurements of both echographists showed high ICC for absolute agree-
ment (0.963, p<0.01). After this pilot study, one of the physicians (AEW) performed all 
intima-media thicknesses measurements in the 476 patients included in this study. 
Carotid artery plaque was scored by the absence of presence of plaque. The definition of 
carotid artery plaque was the presence of any vascular irregularities or widening of the 
carotid artery, with or without protrusion into the lumen (13). 
Laboratory measurements
All patients were instructed to be fasting before venous sampling. Blood glucose was 
analyzed using Breeze®2 glucose meter (Bayer Health Care LLC, Basel, Switzerland). 
Lipid profiles (Total cholesterol, Triglycerides, HDL-cholesterol) were measured using 
commercial enzymatic kits Cat:11489232 for TC and HDL and Cat:11488872 for TG (Roche 
Molecular Biochemicals) and determined using ELISA reader (LabSystem Multiscan, 
MHC347, Finland). LDL-cholesterol was calculated by using the Friedwald calculation.
Sample size calculation
No studies have been performed in high, middle or low income countries that analyzed 
IMT stratified by blood pressure levels. A formal power calculation was therefore not 
possible. The aimed number of included patients (n=500) was based on the capacity of 
the research team that performed IMT measurements to conduct the work within a 2 
week period.
Statistical analysis
For all baseline characteristics data are presented as mean ± SD. The mean IMT is pre-
sented as mean ± SEM. Analysis of variance (ANOVA) and analysis of covariance (AN-
COVA) were used to assess the relation between mean IMT measurements and classes of 
systolic blood pressure. Bonferroni correction was applied for comparison between all 
groups. P values <0.05 were considered to be significant. Model 1 is not corrected for any 
additional ‘classical’ cardiovascular risk factors (ANOVA). Model 2 is corrected for age and 
gender (ANCOVA 1). Model 3 is corrected like model 2 with addition of smoking, blood 
glucose, waist-hip ratio, total cholesterol/HDL ratio, medical history and family history 
(ANCOVA 2). Statistical analysis was done using SPSS statistics 17.0.2 (SPSS Inc., Chicago, 
Illinois, The USA). 
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RESULTS
Demographics
Out of the 500 patients invited, 476 (95.2%) responded and presented at our research 
centre. Of these 476 patients, 471 (99%) had both IMT and blood pressure measured and 
were included in the analysis. Patients’ characteristics are given in table 1. The average 
age was 51 ± 10 years, ranging from 20 to 80 years. There was a slight predominance of 
female patients (58%) and a third of all patients were smokers (33.2%). Pharmacological 
treatment was virtually absent: Fourteen patients (2.9%) used any form of medication 
of whom eight patients (1.7%) were taking anti-hypertensive medication mostly on ir-
regular basis (3 patients used nifedipine, 6 captopril and 3 hydrochlorothiazide). Twenty 
patients (4.2%) had suffered a stroke and/or a myocardial infarction, 30 patients (6.3%) 
had diabetes mellitus type II. A positive familial history of cardiovascular events was 
present in 30 patients (6.3%). The mean waist-hip ratio was 0.89 ± 0.07 (0.92 ± 0.06 in 
male and 0.87 ± 0.06 in female). The mean blood glucose levels measured was 6.1 ± 1.8 
mmol/L. Mean blood pressure was 135 mmHg systolic and 78 mmHg diastolic. Hyperten-
sion (grade I and II) was present in 35.6% of the subjects. The mean total cholesterol 
level was 5.05 ± 1.12 mmol/L, HDL cholesterol was 1.54 ± 0.39 mmol/L, triglycerides 1.30 
± 0.68 mmol/L and the mean calculated LDL-cholesterol level was 2.92 ± 1.01 mmol/L. 
The mean total cholesterol / HDL-cholesterol ratio was 3.44 ± 1.07. Mean carotid artery 
IMT was 635.4 ± 5.1 µm. Mean SCORE-score was 2.4 ± 2.1 %. Carotid plaque was present 
in 16.6% of the patients. (Table 1)
carotid artery IMT and blood pressure class
Blood pressure was measured in 471 patients. Mean blood pressure (±SD) was 111.7/66.8 
(±6.0/6.1) mmHg in the “optimal” blood pressure class group (n=121), 128.4/75.6 (±5.8/7.3) 
mmHg in the “(high) normal” blood pressure class group (n=180), 147.1/85.3 (±5.5/6.0) 
mmHg in the “grade I hypertension” class group (n=95), 166.2/92.2 (±8.3/10.4) mmHg in 
the “grade II hypertension” class group (n=53) and 194.4/101.6 (±18.7/12.1) mmHg in the 
“grade III hypertension” class group (n=22). 
Mean carotid artery IMT (±SEM) was 587.8 (±9.3) µm, 621.5 (±7.6) µm, 653.6 (±10.5) µm, 
717.9 (±14.0) µm and 750.1 (±21.8) µm in the “optimal” blood pressure, “(high) normal” 
blood pressure, “grade I, II and III hypertension” classes, respectively. If corrected for mul-
tiple testing the carotid artery IMT measurements of all blood pressure classes remained 
significantly different compared to the grade II hypertension class (P<0.01). 
To address the potential influence of age and gender, a subsequent analysis was 
performed adjusting for the variables ‘age’ and ‘sex’ (model 2). This resulted in a mean 
IMT (±SEM) of 605.1 (±8.2) µm, 623.7 (±6.5) µm, 647.4 (±9.0) µm, 696.2 (±12.2) µm and 
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respectively (P<0.01). Adjusting for ‘age’, ‘sex’, ‘smoking’, ‘blood glucose’, ‘waist-hip-ratio’, 
‘total cholesterol / HDL-cholesterol ratio’, ‘medical history’ and ‘familial history’ (model 3) 
resulted in a mean IMT (±SEM) of 609.3 (±10.1) µm, 622.7 (±8.1) µm, 653.4 (±11.2) µm, 681.7 
(±16.5) µm and 709.5 (±24.2) µm in the respective blood pressure classes (figure 1).
Table 2 shows the contribution of every individual ‘classical’ cardiovascular risk factor 
on the progression of IMT (model 3). Blood pressure classes significantly contributed to 
carotid artery IMT (P<0.01) regardless of age (p<0.01), gender (p=0.11), blood glucose 
(p=0.73), lipid levels (p=0.49), waist-hip ratio (p=0.68), smoking (p=0.74), medical his-
tory (p=0.48) and familial history (p=0.58). Using LDL-cholesterol instead of the total 
cholesterol / HDL-cholesterol ratio yielded identical results (data not shown).
DIScUSSION
This is the first study that relates blood pressure class to carotid artery intima media 
thickness in a population with a traditional “non western” lifestyle at the secondary 
epidemiological transition. The results show a clear increase of carotid artery intima 
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media thickness with higher blood pressure classes. An effect that remained statistically 
significant after correction for potential confounders. Interestingly, this observation has 
been done in an environment where medication is not yet continuously present. Thus, 
the results probably reflect the real and remarkable strong impact of blood pressure 
class in carotid artery intima media thickness. These results show that the relevance of 
blood pressure stratification is not restricted to subjects in high income countries at the 
third epidemiological transition (7,9,14).
Intriguingly, the effect of blood pressure carotid artery intima media thickness may 
start at an early level of blood pressure elevation. Although, the effect of optimal versus 
(high) normal blood pressure on the intima media thickness did not remain statisti-
cally significant in ANCOVA model 1 and 2, the statistically significant uncorrected data 
(ANOVA) suggest the increase of carotid artery intima media thickness may already 
occur in subjects in the high normal blood pressure group. This is in line with the dose-
effect relation between BP classes and intima media thickness as observed. Importantly, 
the population studied may well reflect the situation in millions of subjects living “non-
Western” societies at the secondary epidemiological transition. Given this strong effect 
of blood pressure class on IMT, in these subjects, and given the fact that increased IMT 
predicts cardiovascular events later in life, the study results underline the importance to 
establish preventive and therapeutic measures for these patients. The knowledge and 
resulting therapeutic means developed in high income countries should be studied and 
figure 2. Cumulative event rate for atherothrombotic events in patients with a first provoked deep vein 
thrombosis (DVT), unprovoked DVT, and in control without DVT
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especially become available in low income countries even if they are at the secondary 
epidemiological transition. 
Our study population had an incidence of grade I and II hypertension of over 35%, which 
is relatively high compared to multiple studies in rural areas in Asia and Africa. (15,16) In 
addition, 17-37% of the 180 patients with “(high) normal” blood pressure may progress 
to hypertension if the data in literature apply to the subjects now studied on Flores 
Island (17). We were however surprised to find this high prevalence of hypertension in 
this population. A consideration regarding this high prevalence is that salt intake on 
Flores Island may be relatively high due to the use of brined seafood (18). Unfortunately, 
we did not collect urine samples to confirm this hypothesis by measuring urine sodium 
secretion. Also local data on salt ingestion have never been gathered and are therefore 
not available. Given this, it is currently not possible to correlate salt intake to blood pres-
sure class, nor to study the relation of sodium intake on the carotid IMT in this popula-
tion(19,20).
It could be argued that the results of our study are confounded by other cardiovascular 
risk factors for instance smoking. Therefore, an analysis for covariance was performed to 
assess the influence of age, gender, smoking, blood glucose level, waist-hip-ratio, total 
cholesterol / HDL-cholesterol ratio, familial history and medical history. The results of 
these analyses (figure 1) show that blood pressure class significantly relate to carotid 
artery intima media thickness. In the ANCOVA models, age significantly contributed to 
IMT. This is in line with the effect of age on IMT previously described in western popula-
tions (21,22). Another weakness is that IMT measurements can not differentiate between 
the intima and media of the vessel wall. The elevation of carotid artery IMT does there-
fore not differentiate between atherosclerotic intima vessel wall thickening and media 
vessel wall hypertrophy due to hemodynamic stimulation by the elevated systolic blood 
pressure (23,24). 
We are aware the study has limitations. Patients with known hypertension and patients 
with a medical or familial history of cardiovascular disease may have been more eager 
to participate in the study. However, the inclusion of patients at ten randomly chosen 
days and the high response rate argue against a sample bias. Second, a cross-sectional 
study design without follow-up period, is not a design to register cardiovascular events. 
Thus, analysis relating high IMT values to future cardiovascular events could not be 
performed in the context of the current study. Thus, the extrapolation of the results of 
multiple studies in Western populations that established carotid artery IMT as marker for 
the presence of atherosclerosis and as approved intermediate endpoint for randomized 
intervention studies may be unjustified and should be confirmed in follow-up studies 
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(8-10) Third, there is a relatively high amount of carotid artery plaque. (25) This could be 
elucidated by defining plaque as any vascular irregularities or widening of the carotid 
artery, with or without protrusion into the lumen. However, the presence of plaque 
increases according to the blood pressure class which is as expected. 
The results of the present study are to our knowledge the first to show the direct relation 
of blood pressure classes and carotid artery IMT in an untreated population at the stage 
of second epidemiological transition. This study underlines the importance of blood 
pressure as risk factor for cardiovascular disease and the potential enormous benefit 
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Several studies showed elevated incidences of atherothrombotic events (ATE) in pa-
tients with unprovoked venous thromboembolic events (VTE). This association remains 
understudied in patients presenting with deep vein thrombosis (DVT). We evaluated the 
incidence of ATE in patients with DVT and compared it to patients with provoked DVT 
and controls without DVT.
Methods 
Patients with compression ultrasonography (CUS) proven unprovoked DVT, provoked 
DVT, and symptomatic patients, in whom DVT was excluded by CUS, were followed and 
scored for the occurrence of ATE. 
Results 
170 patients with provoked, 74 patients with unprovoked DVT and 991 patients without 
DVT were included. During follow-up 128 ATE occurred (incidence 6.5/100 patient-years). 
Adjusted hazard ratio (HR) was not different between patients with DVT and without 
DVT (1.4; 95%CI 0.76-2.4). In contrast, patients with unprovoked DVT suffered ATE more 
frequent than provoked DVT patients (3.16; 95%CI 1.1-9.1) and control patients (HR 2.8; 
95%CI 1.3-5.7). Notably, when fully adjusted for known ATE risk factors the risk differences 
between controls, provoked and unprovoked DVT patients diminished: HR 1.1 (95%CI 
0.47-2.5) and 1.7 (95%CI 0.80-3.6) respectively.
conclusion
 Our study showed that risk of ATE in patients with unprovoked DVT was higher than 
in patients with provoked DVT or control patients. Interestingly, after full adjustment 
for multiple known risk factors, the significant difference between unprovoked DVT 
patients and provoked DVT patients or control patients diminished. This implicates that 
the correlation between ATE and DVT is non-causal and the measured cardiovascular 
risk factors are confounders in this correlation. 
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INTRODUcTION
Several studies have observed an increased risk of atherothrombotic events (ATE) after 
a diagnosis of venous thromboembolism (VTE) of unknown origin (unprovoked) (1-4). A 
meta-analysis by Becattini et al. (5), showed an incidence rate ratio (IRR) of 1.87 for the 
risk of ATE in patients with unprovoked VTE when compared to healthy controls and an 
IRR of 1.86 for the risk of ATE in unprovoked VTE when compared to patients with VTE of 
known origin (provoked). Three of the studies included in this meta-analysis concerned 
patients with pulmonary embolism (PE) (3, 6, 7), while only one study examined the 
incidence of ATE after deep vein thrombosis (DVT) (3). In the latter population-based 
cohort study, the relative risk for overall ATE in the first year after VTE was higher in 
unprovoked PE patients than in unprovoked DVT patients (2.84 vs 1.87) when compared 
to population controls and when population controls were compared to provoked 
PE and provoked DVT, the relative risk was 2.28 and 1.82 respectively (8). Importantly, 
in that study, the incidence of ATE in patients with DVT had been compared with the 
incidence in population controls without VTE, who may have a lower a priori risk for 
arterial disease than patients with established VTE. Moreover, due to the study design, 
Sorensen et al. were unable to adjust for patients’ characteristics and known individual 
cardiovascular risk factors. Therefore, our goal was to further explore the association 
between DVT and ATE by including a control population with more similar baseline 
characteristics than population controls and to collect their individual cardiovascular 
risk factors. Therefore we selected a group of consecutive patients presenting to our 
hospital who were clinically suspected of having DVT, but in whom DVT was ruled out 
by compression ultrasonography (CUS) as a control group. In this prospective cohort 
study, we assessed and compared the incidence of ATE in patients with a first episode 
of CUS confirmed proximal DVT with the ATE incidence of patients in whom DVT was 
suspected but ruled out. Further, we repeated this analysis for patients with provoked 
and unprovoked DVT separately.
METHODS
Study design
A prospective cohort study was conducted to define the risk of ATE and the event-free 
survival in patients with a first unprovoked and/or provoked proximal DVT compared to 
control patients without a medical history of VTE in whom DVT was suspected but ruled 
out. Primary study endpoints were new episodes of confirmed VTE and ATE, the latter 
defined as myocardial infarction, ischemic stroke, transient ischemic attack, intermittent 
claudication, carotid endarterectomy, unstable angina, coronary artery bypass grafting, 
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peripheral arterial angioplasty, bypass or death of unknown cause in the period from 
diagnosis of DVT until 31-12-20109. 
Patients
All in- and out-patients in our hospital with clinically suspected DVT between July 2002 
and December 2005 were eligible for inclusion. Their medical charts were searched 
for the occurrence of study endpoints at the end of the follow-up period. Whenever 
a patient had died before December 2010, the pathology report, whenever available, 
was examined for date and cause of death. This was double checked with data from the 
Office of National Statistics of the Netherlands. The surviving patients were contacted 
by mail and requested to complete a questionnaire with questions regarding medical 
history, smoking status, medication use and current clinical condition. In case the resub-
mitted questionnaires contained missing data, we contacted the patients by telephone. 
Patients who did not respond to our first request were sent a reminder. If patients could 
not be reached, the last medical report of their treating general practitioner was used to 
complete our database. In case of a reported episode of VTE or ATE during the follow-up 
period, information regarding diagnosis, treatment regimen and treatment time was 
collected. The study protocol was reviewed and approved by the Institutional Review 
Board of the Leiden University Medical Centre (LUMC). 
Patients with a first acute DVT
The diagnosis of proximal DVT was based on non-compressibility in the popliteal, femo-
ral and/or iliac veins on compression ultrasonography (CUS). Data on risk factors for DVT 
were derived from the original medical charts. Unprovoked DVT was defined as DVT 
occurring in the absence of risk factors: active malignancy, immobility for more than 
three days or a recent long flight (at least 4 hours), recent surgery or fracture of lower 
extremity, pregnancy or peri-partum period, hormone replacement therapy and use of 
oral contraception. Patients diagnosed with acute DVT were initially treated according 
to hospital policy with low-molecular-weight heparin (LMWH) followed by oral vitamin 
K antagonists (VKA) for at least 3 months for patients with provoked DVT and at least 6 
months for patients with unprovoked DVT. Because therapy with VKA reduces the risk 
for myocardial infarction10 patients with an alternative indication for VKA therapy, in 
whom these anticoagulants could not be withdrawn after a 6-month treatment period, 
were excluded from this analysis.
Patients in whom DVT was suspected but ruled out
The control population consisted of patients in whom a first DVT was clinically suspected 
but ruled out by serial CUS or CUS with a normal D-dimer test11. They were not treated 
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with anticoagulant drugs. As with the proven DVT patients, those with an alternative 
indication for oral anticoagulation were excluded from this analysis.
Statistical analysis
Baseline characteristics are given as mean ± standard deviation (SD). Nominal data are 
presented as the number of patients (N) and the percentage in the study cohort (%). The 
incidence of ATE in patients with provoked and unprovoked DVT compared to patients 
in whom a DVT was clinically suspected but ruled-out by CUS was assessed. Cumulative 
event rates were estimated using a Kaplan-Meier life-table. To rule out the effect of VKA 
on the incidence of ATE, the start date was set at the day of VKA cessation. Hazard ratios 
(HR) were calculated using a Cox proportional hazard model. These were adjusted for 
known confounders including sex, age, malignancy, positive smoking status, hyperten-
sion, diabetes and hypercholesterolemia and a previous history of ATE. Patients with 
(recurrent) thrombosis or non-vascular death were censored in the analysis. Analysis was 
performed using SPSS version 14.0 (SPSS Inc, Chicago, IL).
 RESULTS
Patients
In a total of 1425 patients, the presence of acute DVT was suspected during the inclusion 
period. Because of a prior history of acute VTE, 190 (13%) patients were excluded from 
further analysis. From the remaining 1235 patients, 244 (20%) were diagnosed with and 
treated for DVT, leaving 991 patients (80%) without DVT as control population. Alterna-
tive diagnosis in these latter patients without DVT included Baker’s cyst, thrombophle-
bitis, cellulitis, erysipelas, intramuscular bleeding and varicose veins.
Baseline characteristics of the study population are depicted in Table 1. There were 
significantly more females in the provoked DVT and control groups than in the unpro-
voked DVT group. Provoked DVT patients were significantly younger than the other 
study patients and a history of ATE was significantly less prevalent in unprovoked DVT 
patients. There was no difference within the study groups for the presence of diabetes, 
hypercholesterolemia and smoking. The total number of patient-years (py) was 5882 in 
the entire population, 5169 py in the control patients, 482 py in the patients with pro-
voked DVT and 231 py in the patients with unprovoked DVT. The median follow-up was 
6 years.
Atherothrombotic Events
A total of 128 fatal and non-fatal ATE occurred during the study period in a total of 384 
person years (incidence 6.5/100 py). No significant difference was found in event free 
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survival between all DVT patients compared to control patients without DVT (figure 1) 
(HR 1.4; 95%CI 0.80-2.5). When adjusted for age, sex, smoking, active malignancy, hyper-
tension, diabetes, hypercholesterolemia and a history of a prior ATE, the HR remained 
non-significant (1.4; 95% CI 0.76-2.4).
After categorizing the DVT group in patients with unprovoked and patients with 
provoked DVT, the incidence of ATE in patients with unprovoked DVT was 18/100 py 
(10 events in 41.6 py), 3.4/100 py in patients with provoked DVT (12 events in 16.4 py) 
and 6.3/100 py in control patients (106 events in 325.8 py) without DVT. A significant 
difference was found in the unadjusted event free survival between control patients and 
patients with unprovoked DVT (HR 2.8; 95% CI 1.3-5.7, figure 2) and the event free survival 
between unprovoked and provoked DVT patients (H.R.3.16; 95% CI 1.1-9.1, figure 2). The 
event free survival between patients with provoked DVT patients and control patients 
was not different (H.R. 0.87; 95% CI 0.38-2.0). 
When fully adjusted for known risk factors (age, sex, smoking, active malignancy, hy-
pertension, diabetes, hypercholesterolemia and a history of a prior ATE), the difference 
in event free survival between controls, provoked and unprovoked DVT patients almost 
disappeared (provoked vs. control 1.1; 95% CI 0.47-2.5; unprovoked vs. control 1.7; 95%CI 
0.80-3.6; unprovoked vs. provoked 1.6; 95% CI 0.52-4.6). 
Venous thromboembolic events
A total of 46 fatal and non-fatal VTE occurred during the follow-up period. Fifteen 
control patients without DVT endured a new VTE in a total of 58.9 py (incidence 1.1/100 
py). Recurrent VTE occurred in 14 unprovoked DVT patients (total of 29.4 py, incidence 
12.7/100 py) and in 17 provoked DVT patients (total of 31.8 py, incidence 6.6/100 py). The 












Sex (Female, %)a 725 (59) 598 (60) 102 (60) 25 (34)
Age (years ± SD)a 56 ± 17 57 ± 18 53 ± 17 59 ± 16
History of ATE (n,%)a 142 (12) 124 (13) 15 (9) 3 (4)
Active malignancy (n,%)a 221 (19) 157 (16) 64 (38) -
Smoking (n,%) 187 (15) 148 (15) 27 (16) 12 (16)
Diabetes (n,%) 110 (9) 96 (10) 7 (4) 7 (10)
Hypertension (n,%)a 375 (30) 309 (31) 39 (23) 27 (37)
Hypercholesterolemia (n,%) 195 (16) 163 (16) 18 (11) 14 (19)
Number of patient years in follow-up 5882 5169 482 231
a Significantly different; DVT=Deep Vein Thrombosis; SD=Standard Deviation; ATE=Atherothrombotic Event
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risk for VTE in follow-up was significantly higher in patients with unprovoked DVT than 
in control patients (Relative Risk (RR) 12.5; 95% confidence interval 6.3-25) and in patients 
with provoked DVT than in patients without DVT (RR 6.61; 95% CI 3.4-13). The risk for 
recurrent thrombosis in unprovoked DVT patients was nearly significant higher than in 
patients with provoked DVT (RR 1.89; 95% CI 0.99-3.6).
Deaths
A total of 355 study patients died during the follow-up period. The majority (154 patients, 
43%) died of cancer, 30 patients (8.5%) died of a myocardial infarction, 24 patients (6.8%) 
suffered a fatal stroke, 8 patients (2.3%) had fatal PE. The remaining 139 patients (39.2%) 
died of other reasons, including infections and traumatic events.
DIScUSSION
The results of our study indicate that the risk of ATE in patients with unprovoked DVT 
was higher than in patients with provoked DVT and in control patients in whom DVT was 
clinically suspected but ruled-out by CUS. Interestingly, after full adjustment for multiple 
known risk factors, the significant difference between unprovoked DVT patients and 
provoked DVT patients or control patients diminished considerably. By demonstrating 
this, our study extends earlier observations and implicates that the correlation between 
ATE and DVT is non-causal and that the measured cardiovascular risk factors are con-
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figure 1. Carotid artery intima–media thickness and blood pressure class Korte titels
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Our study design and study population was different from previous reports analyzing 
the incidence of ATE after VTE. Only one previous study examined solely the incidence of 
ATE in DVT patients and compared it to control patients without VTE (3). They found that 
patients with a DVT had an increased risk for the development of ATE, which was most 
pronounced during the first year but persisted after 20 years of follow-up. However, 
this study was performed in a population-based cohort from a nationwide database 
and nationwide patients were used as controls, which may have a lower a-priori risk for 
ATE than patients with proven VTE. The inclusion of patients in whom DVT was clini-
cally expected but ruled out by CUS resulted in a control group with more comparable 
baseline characteristics. In addition, our study is the first study in patients, presenting 
with proximal DVT of the leg, in which it was possible to adjust for known individual 
cardiovascular risk factors and to exclude patients using vitamin K antagonists from the 
analysis. 
Our study group has earlier evaluated the risk for ATE after PE, and identical control 
patients –i.e. in whom PE was suspected but ruled out- were selected to adjust for con-
founding factors (7). Though our unadjusted results are very comparable to this earlier 
study, there is an interesting contrast to the PE cohort with regard to the influence of 
classical ATE risk factors on the adjusted hazard ratio’s for ATE. While the unadjusted 
as well as adjusted hazard ratios for ATE in unprovoked PE patients were significantly 
higher compared to provoked PE and control patients, correction of the hazard ratios 
for traditional ATE risk factors in the DVT cohort resulted in loss of all significant dif-
ferences. Two possible explanations for this difference between DVT and PE patients 
seem obvious. First, since the number of patients in the unprovoked DVT cohort is 
relatively limited, our study could be underpowered for an analysis that includes almost 
10 different correction factors. A second possible explanation could be that risk factors 
-and therefore the pathophysiological mechanism- for PE and DVT are not uniform. For 
instance, a previous study has shown that, when compared to non-carriers, the relative 
risk for the occurrence of DVT was 7.0 in factor V Leiden carriers while the relative risk for 
the occurrence for PE was 2.812. This paradox has also been found in use of oral contra-
ceptives13 and pulmonary diseases, including asthma, COPD and pneumonia (14-16). In 
addition, ATE after PE may occur following another more direct mechanism. One could 
hypothesize that the presence of a thrombus in the pulmonary artery and direct cardiac 
stress by the pulmonary embolus could lead to cytokine release and local inflammatory 
reaction which enhances the progression of already present atherosclerotic plaques (17). 
However, there are no currently published studies that reject or prove this hypothesis. A 
direct causal effect of DVT on future occurrence of ATE is difficult to explain. Considering 
this, the large influence of traditional cardiovascular risk factors on the hazard ratios for 
ATE in patients with unprovoked versus provoked DVT patients and controls might in-
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dicate that these risk factors contribute to both ATE as well as VTE, especially in patients 
with unprovoked DVT.
Strengths of this study include the fact that we used data from the general practitioner 
and the Office of National Statistics of The Netherlands in addition to the medical record 
of our hospital and the questionnaire to score our study endpoints. Therefore no pa-
tients were lost to follow-up. Second, we used well defined and serious medical events 
as study endpoints, which are likely to be recorded and therefore we believe we did not 
miss out any ATE in follow-up. Third, we had an adequately long follow-up period, with 
a total number of 5882 patient years. Limitations of our study were, despite the large 
consecutive sample size, a relatively small number of patients with unprovoked DVT. 
Second, possible confounding factor including the classical ATE risk factors were only 
assessed at baseline. Therefore our analyses were not corrected for patients receiving 
preventive medication for ATE after study inclusion.
In conclusion, our data indicates that patients after unprovoked DVT are at increased 
risk of ATE compared to patients after provoked DVT and control patients without DVT, 
as was previously shown in patients with unprovoked PE. However, full adjustment for 
several well established ATE risk factors diminished these findings. These results raise 
the question whether the known risk factors for ATE and VTE attribute equally in PE and 
DVT patients and contradict a causal relation between ATE and VTE. Large prospective 
trials are needed to identify the underlying mechanism in both PE and DVT patients for 
developing ATE complications and to identify an adequate treatment regimen for future 
arterial and venous complications in patients presenting with a first VTE. This treatment 
could include vitamin-K antagonists, direct factor IIa or Xa inhibitors, aspirin or statins.
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The aims of this thesis were to i) improve the diagnostic management of acute pulmo-
nary embolism (PE), ii) study predictors of adverse clinical outcome of PE, iii) study the 
association between venous thromboembolism (VTE) and arterial thromboembolic 
events (ATE), and iv) highlight the relevance of hypertension in atherosclerosis and the 
effect of aspirin on blood pressure. For this purpose, we conducted a randomized 
controlled trial, several cohort studies and meta-analyses. chapter 1 provides a general 
introduction to this thesis.
chapter 2 is a meta-analysis of 4 prospective management studies (1660 consecutive 
patients) in which the diagnosis of acute PE was excluded on the basis of a “unlikely” 
clinical decision rule (Wells rule ≤4 points) and a normal high sensitive D-dimer test to 
evaluate the safety of such a diagnostic strategy. We demonstrated that this dichoto-
mized threshold of the Wells rule is safe with a negative predicative value (NPV) of 99.7% 
(95%CI 99.0-99.9%). Also, the 3-month mortality risk of PE was very low (0.10%; 95%CI 
0.002-0.46%). In chapter 3, we performed a meta-analysis of 40 studies focusing on the 
risk for contrast induced nephropathy (CIN) and the need for renal replacement therapy 
due to persistent loss of renal function after intravenous contrast enhanced CTPA. In 
19563 patients the weighted incidence of CIN was 6.4% (95% CI 5.0–8.1) and the need 
for renal replacement therapy was 0.06% (95% CI 0.01–0.4). From those numbers, we 
conclude that intravenous contrast media could be safely administered in the overall 
majority of patients with suspected PE. 
Although PE is a potentially lethal disease, it is diagnosed more than a week after 
symptom onset in 17% of the patients. In chapter 4¸ we describe an observational 
prospective outcome study in 113 consecutive patients with CT proven PE to evaluate 
whether patient’s delay is of influence on the thromboembolic burden and right ven-
tricular function by measuring Qanadli-score and right ventricular (RV)/left ventricular 
(LV)-ratio. In a linear analysis, neither the Qanadli score (R2 0.003, p=0.726) nor the RV/
LV-ratio (R2 <0.001 p=0.991) were associated with this patient’s delay. Also, the mortality 
rates after 6 weeks of follow-up did not significantly differ in patients with and without 
delay (Odds ratio: 0.65; 95% CI 0.08 — 5.6). Hence, we concluded that we could not 
demonstrate an association between patient’s delay and either heavier thrombus load, 
more severe right ventricular dysfunction or mortality. 
BNP or NT-pro-BNP, the inactive N-terminal of BNP, is a known biomarker for unfavour-
able clinical outcome in patients with acute PE. Whether the elevation in BNP level is 
caused by RV distress due to pulmonary artery obstruction or whether the rise is caused 
by LV distress due to hemodynamic changes was debated up till recently. In chapter 
5 we measured RV and LV ejection fraction (EF) and end-diastolic volumes (EDV) in 
109 patients with and 226 patients without PE, and related those to NT-pro-BNP levels. 
In patients with PE, an increased RVEF (β-coefficient (95% confidence interval [CI)) 
–0.044 (± –0.011); p<0.001) and a higher RV end-diastolic volume (β-coefficient 0.005 (± 
108 Chapter 8
0.001); p<0.001) were significantly correlated to NT-pro-BNP, while no correlation was 
found with LVEF (β-coefficient 0.005 (± 0.010); p=0.587) and LV end-diastolic-volume 
(β-coefficient –0.003 (± 0.002); p=0.074). In patients in whom PE was suspected but ruled 
out by CTPA, we found a strong correlation NT-pro-BNP levels and LV function. With this 
study we have provided evidence that elevated NT-pro-BNP levels in PE patients are 
indeed caused by RV distress.
In chapter 6, we examined the effect of blood pressure on intima media thickness, as 
a measure of atherosclerosis, in a population at the second epidemiological transition, 
in which mortality is mostly characterized by infectious diseases. We found that IMT 
significantly differed between BP classes (P<0.001). Mean (±SEM) IMT was 587.8 (±9.3)
mm, 621.5 (±7.6)mm, 653.6 (±10.5)mm, 717.9 (±14.0)mm, and 750.1 (±21.8)mm for ‘optimal’, 
‘(high) normal’, ‘grade-I, grade-II, and grade-III hypertension’ classes, respectively. After 
adjustment for cardiovascular risk factors, similar results were obtained. Therefore we 
conclude that there is indeed a strong correlation between blood pressure class and 
intima media thickness, which already occurs in the “high normal” blood pressure class. 
In chapter 7, we evaluated the association between VTE and ATE by comparing the 
incidences of cardiovascular events (defined as myocardial infarction, ischemic stroke, 
transient ischemic attack, intermittent claudication, carotid endarterectomy, unstable 
angina, coronary artery bypass grafting, peripheral arterial angioplasty, bypass or death 
of unknown cause) in patients with provoked and unprovoked deep vein thrombosis 
(DVT) and in patients in whom DVT was suspected but ruled out by compression ultra-
sonography. After a median follow-up of 6 years, no significant difference was found 
in the incidence of ATE in patients with and without DVT (HR 1.4; 95%CI 0.80-2.5). If the 
DVT group was separated in provoked and unprovoked DVT, we could demonstrate a 
significant difference in the unadjusted event free survival between control patients 
and patients with unprovoked DVT (HR 2.8; 95% CI 1.3-5.7) and the event free survival 
between unprovoked and provoked DVT patients (H.R.3.16; 95% CI 1.1-9.1). The event 
free survival between patients with provoked DVT patients and control patients was not 
different (H.R. 0.87; 95% CI 0.38-2.0). When fully adjusted for known cardiovascular risk 
factors (age, sex, smoking, active malignancy, hypertension, diabetes, hypercholesterol-
emia and a history of a prior ATE), the difference in event free survival between controls, 
provoked and unprovoked DVT patients almost disappeared (provoked vs. control 1.1; 
95% CI 0.47-2.5; unprovoked vs. control 1.7; 95%CI 0.80-3.6; unprovoked vs. provoked 1.6; 
95% CI 0.52-4.6). We concluded that patients with an unprovoked DVT are at increased 
risk for ATE, which could largely be explained by overlapping cardiovascular risk factors.. 
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fUTURE PERSPEcTIVES
The diagnostic management of acute pulmonary embolism (PE) has evolved during the 
last 20 years. Nowadays, emergency doctors can rely on safely excluding this condition 
by a clinical decision rule in combination with D-dimer blood test levels. However, incor-
rect use of tests like D-dimer and the fear for consequences of missed PE has resulted in a 
dramatic increase of patient undergoing further imaging. This results in unnecessary ra-
diation exposure and over use of computed tomography pulmonary angiogram (CTPA). 
Therefore an even more simplified diagnostic algorithm that can easily be implemented 
and more closely fits the busy clinical practice should be searched for. A promising new 
diagnostic algorithm is that of ‘Years’ (1). This algorithm consists of 3 items (clinical signs 
of DVT, hemoptysis and the subjective clinical assessment whether PE is more likely than 
another diagnosis or not) in combination a D-dimer blood test. In patients scoring none 
of the items, PE can safely be discarded without CTPA, in case of a D-dimer blood test 
<1000 ng/ml. In patient in whom at least 1 of the items is positive, a D-dimer cut-off of 
<500 ng/ml is used to exclude PE without CTPA. All other patients undergo CTPA. The 
YEARS algorithm has been proven to reduce the number of necessary CT-scans even 
further and to be safe in post-hoc analyses of the Christopher and Prometheus studies. 
The safety and efficiency of this algorithm is currently being studied in a Dutch prospec-
tive outcome study.
Another possibility to lower the risk of radiation and contrast mediated nephropathy is 
the use of magnetic resonance-pulmonary angiography (MRPA).MRI has been reported 
to have high specificity (97-100%) and good inter-observer agreement (kappa value 
0.93; 0.88-0.99)for the diagnosis of acute PE, although only in analyses that excluded 
technically inadequate scans (2). However MRPA frequently resulted in technically inad-
equate and non-interpretable images (30%) especially in centres not routinely perform-
ing MRPA. Overall sensitivity (78.7-89.6%) (2) of MRPA was shown to be comparable to 
that of single-slice helical CT (62-78%) (3). Hence, with the current available technique 
MRPA is not suitable for use in the day to day clinical practice. Hypothetically, inclusion 
of compression ultrasonography after normal MRPA could possibly complement this 
lack of sensitivity. In addition, further technical improvement could overcome current 
limitations. Especially young and pregnant patients, in whom exposure to radiation is 
associated with the greatest risk, could benefit from the availability of MRPA. 
Second, venous and arterial thromboembolic events should no longer be regarded as 
two worlds apart. For instance, identification of VTE patients at especially high risk for 
arterial cardiovascular events is relevant since these patients may benefit from modified 
treatment regimens including preventive use of antiplatelet and cholesterol synthesis 
inhibiting treatment. Prospective studies are needed to examine the association of the 
presence and extend of cardiovascular risk factors at the moment of VTE diagnosis and 
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the future risk of suffering from ATE. Also, the cost-efficacy of implementation of strict 
cardiovascular disease prevention strategies in patients with acute VTE should be the 
focus of future research.
Finally, management of hypertension remains a challenge. In this thesis, we have 
confirmed the well-known role of hypertension in the occurrence of arterial throm-
boembolic events. Despite current antihypertensive regimens, therapy resistant 
hypertension, is estimated to occur in ~13 % of patients (4;5). This resistant hypertension 
is caused by several factors, including incompliance, irreversible arterial stiffness due 
to late diagnosis of hypertension and lack of recognition of secondary causes such as 
sleep apnea. Therefore new treatment regimens to overcome these factors are needed. 
These treatment regimens should concentrate on improving therapeutic adherence by 
increasing patient awareness but also optimize therapeutic effect of current and future 
medication. Promising new options are neprilysin inhibitors, which have been shown to 
be effective in heart failure patients (6). Also optimizing the time of intake of medica-
tion, based on circadian rhythm, could reduce the amount of medication needed and 
thereby improve patient adherence. A previous study (7) showed that aspirin taken at 
awakening significantly lowered plasma renin and urine dopamine and norepinephrine 
excretion when compared to taken at bedtime. This is a pathophysiologically plausible 
mechanism in the reduction of blood pressure. Another study showed that aspirin at 
bedtime significantly reduced COX1-dependent platelet activity when compared to 
aspirin taken on awaking. This could potentially prevent an additional amount of arterial 
thromboembolic events (8).  Therefore, future clinical trials should investigate whether 
switching aspirin intake to bedtime lowers the blood pressure and ultimately lowers the 
risk of arterial thromboembolic events. A promising new invasive therapeutic option 
is carotid sinus baro-receptor stimulating therapy. This is an implantable device that 
electrically stimulates the carotid baro-receptors. This ultimately leads to decreased 
sympathetic nerve activity, but also decreased heart rate, cardiac contractility and acti-
vation of the renin-angiotensin-aldosteron system and ADH release (9). A phase-III study 
showed a significant reduction of systolic blood pressure of up to 35 mmHg in patients 
with therapy resistant hypertension (10). However, this trial did not meet a pre-specified 
safety condition: the procedural safety had an event-free rate ~75% while 82% was pre-
specified. Future clinical trials should further address the safety and efficacy of carotid 
sinus baro-receptor stimulating therapy in the treatment of hypertension.
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Dit proefschrift bevat studies die als doel hebben om 1) de diagnostiek van longem-
bolieën te verbeteren, 2) bij patiënten met een longembolie de factoren te ontdekken 
die een slechte uitkomst veroorzaken, 3) een associatie aan te tonen tussen veneuze 
en arteriële trombose en 4) het belang van hoge bloeddruk in het ontwikkelen van 
aderverkalking te benadrukken. 
Hoofdstuk 1 is een algemene inleiding over het ontstaan en de presentatie van ve-
neuze en arteriële trombose.
Hoofdstuk 2 is een meta-analyse van vier prospectieve studies die 1660 opeenvol-
gende patiënten behelst. In al deze studies werd onderzocht of een longembolie 
veilig kan worden uitgesloten op basis van een klinische beslisregel met als uitkomst 
“onwaarschijnlijk” (Wells ≤ 4 punten) en een normale D-dimeertest. Wij demonstreerden 
dat dit algoritme veilig is met een negatief voorspellende waarde van 99.7% met een 
95% betrouwbaarheidsinterval ( 95% CI) van 99.0%-99.9%. De kans op overlijden aan 
een longembolie in de daaropvolgende 3 maanden was 0.1.% (95% CI 0.002%-0.46%).
In hoofdstuk 3 wordt een meta-analyse besproken, waarin werd gekeken hoeveel pa-
tiënten er niervervangende therapie nodig hebben wegens blijvend nierfunctieverlies 
na het toedienen van intraveneus contrast bij de diagnostiek naar longembolieën. In de 
19.563 geïncludeerde patiënten was er een gewogen incidentie van contrastnefropatie 
in 6.4% (95% CI 5.0%-8.1%). Niervervangende therapie was in 0.06% (95% CI 0.01%-0.4%) 
van de patiënten nodig. Op basis van deze gegevens concluderen wij dat intraveneus 
contrast veilig toegediend kan worden in de grote meerderheid van de patiënten ver-
dacht voor een longembolie.
Ondanks dat longembolie een potentieel dodelijke ziekte is, wordt de diagnose in 
17% van de gevallen pas na meer dan een week na het starten van symptomen gesteld. 
In hoofdstuk 4 beschrijven we een observationele prospectieve uitkomststudie in 113 
opeenvolgende patiënten met een op CT bewezen longembolie. In deze groep patiën-
ten werd gekeken of de duur tussen het starten van de klachten en het stellen van de 
diagnose van invloed was op de grootte van de trombose en de rechter-ventrikelfunctie. 
Dit werd gedaan door de Qanadli-score en de rechter-ventrikel/linker-ventrikel-ratio te 
meten. Uit een lineaire analyse werd aangetoond dat een latere presentatie geen in-
vloed had op de Qanadli-score (R2 0.003, p=0.726), noch op de rechter-ventrikel/linker-
ventrikel-ratio (R2 <0.001, p=0.991). De mortaliteit na 6 weken was ook niet verschillend 
in de patiënten met ten minste 1 week bestaande klachten, vergeleken met patiënten 
met minder dan een week klachten (Odds ratio: 0.65; 95% CI 0.08 — 5.6). Hieruit maakten 
wij op, dat de duur tot presentatie niet van invloed is op de ernst van de longembolie in 
de zin van grotere trombose, verminderde rechter-ventrikelfunctie of mortaliteit.
Er zijn meerdere biomarkers die een ongunstige uitkomst voorspellen in patiënten 
met een longembolie. BNP of NT-pro-BNP, het inactieve N-terminaal van BNP, is een 
van die biomarkers. Het is echter niet duidelijk of dit gemaakt wordt door rek op het 
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rechter-ventrikel, veroorzaakt door obstructie van de longembolie, of dat het komt 
door hemodynamische veranderingen in het linkerventrikel. In hoofdstuk 5 werd de 
rechter- en linker-ventrikel-ejectiefractie en het einddiastolisch volume gemeten in 
109 patiënten met een longembolie en in 226 patiënten bij wie een longembolie op CT 
was uitgesloten. De NT-pro-BNP-waardes werden tussen deze twee groepen vergele-
ken. In patiënten met een longembolie was een betere rechter-ventrikel-ejectiefractie 
(β-coëfficiënt -0.044 (95% CI ±-0.011); p < 0.001) en een hogere rechter-ventrikel-einddi-
astolisch volume (β-coëfficiënt 0.005 (95% CI ±0.001); p=0.587), significant gecorreleerd 
met NT-pro-BNP-waardes. Er is daarentegen geen relatie tussen linker-ventrikel-
ejectiefractie (β-coëfficiënt 0.005 (± 0.010); p=0.587) en linker-ventrikel-einddiastolisch 
volume (β-coëfficiënt -0.003 (± 0.002); p=0.074) met NT-pro-BNP-waardes. In de 
patiënten waarin een longembolie is uitgesloten op CT was er juist een sterke relatie 
met linker-ventrikelfunctie en NT-pro-BNP-waardes. Middels deze studie hebben we 
bewijs geleverd dat verhoogde NT-pro-BNP-waardes in patiënten met een longembolie 
veroorzaakt worden door stress op het rechter-ventrikel.
In hoofdstuk 6 hebben we naar de associatie gekeken tussen veneuze en arteriële 
trombose. Dit hebben we gedaan door de incidentie van cardiovasculaire events (om-
schreven als myocardinfarct, beroerte, transient ischemische attack (TIA), claudicatio 
intermittens, carotisendarterectomie, instabiele angina pectoris, bypassoperatie, 
operatie aan de beenvaten wegens atherosclerose en dood met onbekende oorzaak) 
te vergelijken in patiënten met uitgelokte en niet-uitgelokte diep-veneuze trombose en 
patiënten waarin een diep-veneuze trombose werd verdacht, maar uitgesloten middels 
echografie. Na een gemiddelde follow-up van 6 jaar was er geen verschil in incidentie 
van cardiovasculaire events tussen patiënten met en zonder een diep-veneuze trombose 
(HR 1.4; 95% CI 0.80-2.5). Als de groep met patiënten met een diep-veneuze trombose 
werd opgesplitst in uitgelokt en niet-uitgelokt, dan waren er wel significante verschil-
len. In de onaangepaste event free survival-analyse tussen de gezonde controlegroep 
en patiënten met een niet-uitgelokte diep-veneuze trombose, behelsde dit een hazard 
ratio van 2.8 (95% CI 1.3-5.7) en tussen de uitgelokte en niet-uitgelokte trombose was 
de hazard ratio 3.16 (95% CI 1.1-9.1). De hazard ratio tussen patiënten met een uitge-
lokte trombose en de controlegroep was niet verschillend (HR 0.87; 95% CI 0.38-2.0). Na 
volledige correctie met de bekende cardiovasculaire risicofactoren (namelijk: leeftijd, 
geslacht, roken, maligniteit, hypertensie, diabetes mellitus, hypercholesterolemie en 
een belaste voorgeschiedenis) verdwenen zo goed als alle verschillen tussen de drie 
groepen (uitgelokt vs controle HR 1.1; 95% CI 0.47-2.5; niet-uitgelokt vs controle HR 1.7; 
95% CI 0.80-3.6; niet-uitgelokt vs uitgelokt HR 1.6; 95% CI 0.52-4.6). Hieruit concludeer-
den wij dat patiënten met een niet-uitgelokte diep-veneuze trombose een verhoogd 
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risico op arteriële complicaties hebben, die grotendeels verklaard kunnen worden door 
reeds bekende cardiovasculaire risicofactoren. 
Hypertensie is een van deze risicofactoren. In het jaar 2000 waren er wereldwijd 972 
miljoen mensen met hypertensie. De verwachting is dat dit aantal alleen maar zal stij-
gen tot 1.56 miljard in 2025. In hoofdstuk 7 bekeken we het effect van hypertensie op de 
vaatwand, middels het meten van de intima media-dikte (IMT), in een populatie die de 
tweede epidemiologische transitie ondergaat (de oorzaak van overlijden verschuift van 
infectieziekten naar hart- en vaatziekten). Wij vonden dat de IMT significant verschilde 
tussen de hypertensie-klasses (p<0.001). De gemiddelde (±SEM) IMT was 587.8 (± 9.3)
mm, 621.5 (±7.6)mm, 653.6 (±10.5)mm, 717.9 (±14.0)mm, en 750.1 (±21.8)mm in respectie-
velijk de klasses “optimaal”, “hoog normaal”, “graad I hypertensie”, “graad II hypertensie” 
en “graad III hypertensie”. Na correctie voor bekende risicofactoren vonden we verge-
lijkbare resultaten. Aan de hand hiervan concludeerden wij, dat er inderdaad een sterke 
correlatie is tussen de mate van hypertensie en de IMT en dit effect is al aantoonbaar in 
patiënten met “hoog-normale” bloeddruk.
Toekomstperspectieven
De diagnostiek van acute longembolieën is de afgelopen 20 jaar snel veranderd. He-
dendaagse artsen kunnen vertrouwen op een klinische beslisregel in combinatie met 
een D-dimeer om een longembolie onwaarschijnlijk te maken. Echter, het verkeerd 
implementeren van deze beslisregel en de angst om een longembolie te missen, heeft 
geresulteerd in een forse toename van het aantal patiënten dat alsnog een beeldvor-
ming ondergaat. Hierdoor volgt een onnodige stralingsbelasting en meer CT-scans die 
verricht moeten worden. Daarvoor is het belangrijk om de beslisregels te blijven verbe-
teren. Deze moeten makkelijker en sneller te hanteren zijn om bruikbaar te blijven op 
een drukke eerste hulp. Een veelbelovende nieuwe beslisregel is de “YEARS-score”. Deze 
beslisregel bestaat uit slechts drie punten (klinische tekenen van een diep-veneuze trom-
bose, haemoptoë en het subjectieve punt of een longembolie de meest waarschijnlijke 
diagnose is) in combinatie met een D-dimeer. In patiënten die geen punten scoren, kan 
een longembolie zonder beeldvorming veilig worden uitgesloten bij een D-dimeer van 
<1000 ng/ml. In patiënten die ten minste 1 punt scoren is de grenswaarde een D-dimeer 
<500 ng/ml. Alle andere patiënten ondergaan beeldvorming. De “YEARS-score” heeft in 
de Christopher en Prometheus-studie post hoc reeds bewezen dat hij veilig is te gebrui-
ken en het aantal CT-scans reduceert. Momenteel is er een prospectieve uitkomststudie 
bezig om de veiligheid en effectiviteit van deze score verder te bestuderen. 
Een andere mogelijkheid om radiatie en de kans op contrastnefropatie te verlagen is 
het gebruik van een Magnetic Resonance Pulmonary Angiography (MRPA). MRI heeft 
reeds bewezen een hoge specificiteit (97-100%) en goede inter-observer agreement 
(kappa-waarde 0.93; 0.88-0.99) te zijn in de diagnostiek naar longembolie. Echter, al 
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deze analyses excludeerden de technisch inadequate beelden. Juist deze technisch 
inadequate en niet te interpreteren beelden komen frequent voor bij MRPA (30%), met 
name in centra die dit onderzoek niet frequent verrichten. De sensitiviteit van MRPA 
(78.7-89.6%) is vergelijkbaar met single-slice CT (62-78%). Deze sensitiviteit zou hypo-
thetisch verbeterd kunnen worden door een echo van de benen te verrichten bij een 
negatief resultaat. Echter, dit is met de hedendaagse beschikbaarheid van de MRI nog 
geen adequaat alternatief en verbeteringen van de techniek zouden huidige limitaties 
moeten doen vergeten. Vooral jonge en zwangere patiënten, in wie straling het meeste 
risico geeft, kan de MRPA uiteindelijk veelbelovend zijn. 
Ten tweede, veneuze en arteriële trombose moeten niet langer gezien worden als 
twee verschillende identiteiten. Het identificeren van patiënten met veneuze trombose 
die een verhoogd risico hebben op arteriële trombose is zeer belangrijk, omdat zij po-
tentieel kunnen profiteren van plaatjesremming en cholesterolverlagers. Prospectieve 
studies zijn nodig om het verband tussen cardiovasculaire risicofactoren bij patiënten 
met een veneuze trombose en het risico op een arteriële trombose uit te kristalliseren. 
Deze studies moeten zich ook richten op de kosteneffectiviteit van strikte cardiovascu-
laire preventie in patiënten met veneuze trombose. 
Als laatste blijft het management van hypertensie een uitdaging. In dit proefschrift 
hebben we nogmaals het verband aangetoond tussen hypertensie en het ontwikke-
len van arteriële trombose. Ondanks onze huidige behandelingsmogelijkheden, blijft 
therapieresistente hypertensie (13% van de patiënten) een groot probleem. Therapiere-
sistente hypertensie is het gevolg van meerdere factoren waaronder therapie-ontrouw, 
onomkeerbare vaatstijfheid door het te laat stellen van de diagnose en de verminderde 
alertheid op secundaire oorzaken, zoals het obstructieve slaapapneusyndroom. Nieuwe 
behandelmethode zijn nodig om deze factoren te overkomen. Deze behandelmethode 
moet zich aan de ene kant richten op het verbeteren van de therapietrouw door patiën-
ten bewuster te maken van de risico’s, en aan de andere kant moet het therapeutische 
effect van de huidige en toekomstige medicatie worden geoptimaliseerd. Veelbelovende 
nieuwe middelen zijn neprilysine-remmers, welke reeds hebben aangetoond zeer ef-
fectief te zijn bij patiënten met hartfalen. Ook het tijdstip van inname van de medicatie 
aan de hand van het cicardiaanse ritme is van groot belang. Dit kan de hoeveelheid 
medicatie verminderen en daarmee de therapietrouw verbeteren. Zo heeft een eerdere 
studie aangetoond dat aspirine ingenomen voor het slapen gaan, het serum renine en 
urine dopamine en norepinefrine significant verlaagt ten opzichte van inname in de 
ochtend. Op basis van dit pathofysiologische mechanisme kan aspirine dus aanvullend 
gebruikt worden om de bloeddruk te verlagen. Prospectieve studies zijn nodig om dit 
effect te bevestigen. Een andere veelbelovende, nieuwe invasieve therapeutische optie 
is carotis baroreceptor-stimulerende therapie. Dit is een implementeerbaar apparaat 
dat de carotis baroreceptor stimuleert met behulp van elektriciteit. Dit leidt uiteindelijk 
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tot verminderde sympatische activiteit en daarmee tot een verlaging van de hartslag, 
verlaging van de rek op het hart, verminderde activatie van het renine-angiotensine-
aldosteron-systeem en verminderde ADH-afgifte. Een recente fase-III-studie presen-
teerde een significante reductie van de bloeddruk tot wel 35mmHg in patiënten met 
therapieresistente hypertensie. Echter, dit onderzoek haalde niet de vooraf gestelde 
veiligheidsmarges; de procedure werd in 75% van de gevallen zonder complicaties uit-
gevoerd, waar een minimum van 82% was vereist. Toekomstige klinische onderzoeken 
moeten zich verder richten op de veiligheid en effectiviteit van carotis baroreceptor-
stimulatie in de behandeling van therapieresistente hypertensie.
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